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ABSTRACT 
 
William Paul Dunworth:  Genetic Mouse Models Elucidate the Role of 
Adrenomedullin in Cardiovascular Development and Disease 
 
(Under the direction of Dr. Kathleen M. Caron) 
 
Adrenomedullin (AM) is a highly conserved, secreted 52 amino acid peptide 
that functions in physiological processes within the nervous, reproductive, and 
cardiovascular systems.  AM is nearly ubiquitously expressed, but most highly 
expressed from the vasculature, lungs, and heart.  During cardiovascular stresses 
including myocardial infarction, hypertension, renal failure and normal pregnancy, 
AM serum levels are elevated suggesting that AM functions as a cardioprotective 
factor.  AM signals through a unique paradigm of G-protein coupled receptor 
(GPCR) signaling in which the affinity of calcitonin receptor-like receptor 
(CLR=protein, Calcrl=gene) for its ligands, AM or calcitonin gene-related peptide, is 
dictated by a family of single-pass transmembrane proteins called receptor activity 
modifying proteins (RAMPs).  Ramp2-CLR and Ramp3-CLR specifically bind AM 
while RAMP1-CLR functions as the CGRP receptor.  Research presented in this 
dissertation aims to further our understanding of AM signaling in mammalian 
cardiovascular physiology through the utilization of genetic mouse models and in 
vitro approaches.   
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I demonstrate that gene-targeted knockout mice of AM, Calcrl, and Ramp2 are 
embryonic lethal from specific defects in lymphatic endothelial cell (LEC) 
proliferation resulting in generalized interstitial edema.  Within this study, I present a 
model in which AM signaling components are enriched during LEC differentiation 
which, in the absence of AM signaling, explains the observed hypoplastic lymphatic 
vascular development.  I also investigated whether a loss in LEC barrier function 
could have contributed to this phenotype.  While I found no difference in the ultra 
structural features or expression of LEC junctional components in knockout mice, I 
show that in vivo and in vitro AM stabilizes the LEC barrier and can completely 
abrogate the highly permeabilizing actions of vascular endothelial growth factor A, 
supporting an important role of AM signaling in LEC barrier regulation.  In a separate 
study, I generated and characterized a vascular smooth muscle cell-specific Calcrl 
deficient mouse.  These mice survived to adulthood with no defects in the regulation 
of basal blood pressure or cardiovascular function which may be due to 
compensation by other hemodynamic mechanisms.  Together, these studies have 
built a solid foundation that will one day benefit future clinical applications of AM in 
lymphatic and vascular smooth muscle pathologies.   
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The Multifunctional Adrenomedullin Peptide 
Adrenomedullin (AM) is a highly conserved 52 amino acid peptide and a 
member of the calcitonin peptide superfamily which also includes calcitonin gene-
related peptide (CGRP), amylin, intermedin, and calcitonin.  The AM secondary 
structure includes a 6 amino acid ring formed by disulfide bonds between residues 
16 and 21.  Also, the C-terminal tyrosine residue is amidated by peptidyl glycine α 
monooxygenase (PAM) [1].  Both of these features are necessary to confer the 
biological activity of AM. 
Adrenomedullin was initially isolated from human pheochromocytoma and 
noted for its ability to increase cAMP levels in human platelets and cause a potent 
hypotensive response in rats [2].  AM is expressed and secreted by nearly all 
mammalian tissues and cell types but is most strongly expressed in the endothelial 
cells and vascular smooth muscle cells of the heart [3], lungs [4], and vasculature [5, 
6].  As a circulating hormone, plasma levels of AM have been found in the 
concentration range of 2 -10 picomolar [7].   In addition to its aforementioned 
function as a vasodilator, AM is involved in angiogenesis [8], vascular permeability 
[9], growth and apoptosis [10], renal function [11], bronchodilation [12] , 
neurotransmission [13], and anti-microbrial defense [14].  Several factors stimulate 
AM production and secretion including hypoxia [15], oxidative stress [16], sheer 
stress [17], vasoconstrictors such as endothelin-1 and angiotensin II [18], and 
inflammatory cytokines such as TNF-α, IL-1β, and interferon-1γ [19].    
 As shown in Figure 1.1, which summarizes findings from over 60 
independent investigations, plasma levels of AM are significantly increased in a wide 
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range of physiological stresses from normal pregnancy to cancer.  Of great 
significance, plasma levels of AM are elevated in many forms of cardiovascular 
disease including arterial hypertension [20], sepsis [21], congestive heart failure [3], 
myocardial infarction [22] and renal disease [23] which together suggest a protective 
role for AM in the cardiovascular system.  However, exactly how AM elicits its 
cardioprotective effects remains largely unknown and subsequently, represents an 
active field of research in hopes of manipulating AM function in a clinical setting. 
 
AM Signaling Through a Unique GPCR Paradigm 
The mechanism through which AM elicits its cellular effects represents a 
unique system of G protein-coupled receptor (GPCR) signaling.  Initially, three 
putative orphan receptors (calcitonin receptor-like receptor (CLR=protein; 
Calcrl=gene name), L1, and RDC-1) were receptor candidates for AM since they 
could bind AM at similar affinities and could generate a dose-dependent cAMP 
response [24-28].  However, a consensus as to which receptor was the putative AM 
receptor could not be reached due to conflicting data and irreproducible results [27, 
29-31].  At last, CLR was recognized as the most likely AM receptor after the 
discovery of a novel class of single-transmembrane domain proteins called receptor 
activity modifying proteins (RAMPs), which helped to demystify the confusion 
surrounding the AM receptor [31].  From this landmark discovery, it was determined 
that RAMPs dictate ligand specificity by associating with CLR at the plasma 
membrane.  As depicted in Figure 1.2, a RAMP1-CLR heterodimer confers a 
receptor for calcitonin gene-related peptide (CGRP) while a RAMP2-CLR or 
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RAMP3-CLR heterodimer functions as a receptor for AM.  Therefore, the spatial and 
temporal expression patterns of the RAMPs determine the cellular response to either 
AM or CGRP.  It should be noted that since the discovery RAMPs, several other 
class II GPCRs have been demonstrated to interact with RAMPs in a similar fashion 
including calcitonin receptor, glucagon receptor, and vasoactive intestinal 
peptide/pituitary adenylate cyclase activating peptide 1 receptor, among others [32, 
33].   
 Our laboratory was the first to use gene-targeted knockout mouse models to 
confirm the identity of the functional AM receptor.  Specifically, deletion of AM, 
Calcrl, or Ramp2 resulted in embryonic lethality at mid-gestation from generalized 
edema and severe cardiovascular defects including hypoplastic lymph sacs, thinner 
vascular smooth muscle walls, and disorganized, smaller hearts [34-36].  The fact 
that all 3 KO mouse models had similar phenotypes provided the first in vivo genetic 
evidence that RAMP2-CLR functions as a bonafide AM receptor during 
development.  Further, the similarity of the AM signaling null mouse phenotype with 
other mouse models describing defects in lymphatic vascular development, such as 
the Prox1 and VEGFC null mice suggested to us that AM signaling may play an 
essential role in this process [37, 38]. 
 
AM in Endothelial Cell Biology 
The vascular endothelium consists of a thin layer of endothelial cells (ECs) 
that line the interior of the entire circulatory system, from the large coronary vessels 
of the heart to the smallest capillaries.  The main function of the circulatory system is 
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to maintain homeostasis by coordinating proper gas, nutrient, and waste exchange 
to and from cells.  ECs are a specialized type of epithelium that differentiate from 
endothelial progenitors during early embryonic development, in a process termed 
vasculogenesis, to form the primary vascular plexus.  Interestingly, AM has been 
shown to promote arterial differentiation of cultured mouse embryonic stem cells 
through a cell signaling cascade that involves cAMP-mediated activation of Notch 
signaling [39].  Furthermore, down regulation of CLR in zebrafish resulted in loss of 
arterial identity of the dorsal aorta, suggesting that AM signaling through CLR plays 
a non-redundant role in arterial differentiation [40]. 
Vasculogenesis is followed by angiogenesis, which by definition includes the 
sprouting and branching of pre-existing vessels to form the functional vascular 
network.  At the cellular level, angiogenesis includes the processes of EC 
proliferation, migration, and tube formation and remodeling.  AM acts on ECs in an 
autocrine / paracrine manner as an angiogenic factor [41].  Using cultured human 
umbilical vein endothelial cells (HUVECs), Miyashita et al showed that AM was a 
strong proliferative and migratory factor [42].   AM can also induce HUVEC 
differentiation to tube-like structures on Matrigel [8].  These cellular effects occur 
through several downstream intracellular pathways, including activation of mitogen-
activated protein kinase (MAPK), Akt, and focal adhesion kinase (FAK) [43, 44].  
These in vitro results have been recapitulated in vivo by Iimuro et al where AM 
treatment increased capillary density in both the hind limb ischemia model and 
transplanted tumors [45].  Interestingly, AM administration increased the local 
expression of vascular endothelial growth factor (VEGF), a finding supported by in 
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vitro studies [45, 46].  This finding, together with the observation that AM 
heterozygote (AM+/-) mice express lower amounts of VEGF [45], strongly suggest 
that a synergistic relationship between exists AM and VEGF.  VEGF is known as the 
most potent and predominant angiogenic factor.  Recently, it has been suggested 
that AM signaling through RAMP2-CLR could transactivate the VEGF receptor 
leading to increased downstream angiogenic effects [47].  Exactly how AM and 
VEGF interact molecularly remains an intense area of investigation since both pro-
angiogenic factors are highly expressed in many forms of cancer and have 
prognostic value (rev. [48, 49]).   
AM also functions as an anti-apoptotic, pro-survival factor in ECs.  Notably, 
both AM and Calcrl contain hypoxia-response elements in their promoter regions, 
which increases their gene expression during low oxygen conditions, thereby 
promoting EC survival, as well as angiogenesis [50, 51].  Several studies have 
elucidated the mechanisms through which AM functions to prevent EC death. A 
study by Kato et al demonstrated that AM could promote cell survival of rat ECs in a 
mechanism independent of the activation of adenylate cyclase and cAMP [52].  
Utilizing HUVECs, Sata et al found that the anti-apoptotic function of AM was cGMP 
independent but could be repressed by nitric oxide (NO) inhibitor L-NAME, 
suggesting a NO-dependent mechanism [53].  More recently, it was found that AM 
treatment of serum-deprived ECs increased the expression of Max, a transcription 
factor that heterodimerizes with c-Myc to promote cell survival [54].  Therefore, it 
appears that the intracellular signaling mechanisms that regulate AM-mediated EC 
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proliferation and survival may differ, which highlights the multi-functional role and 
complexity of AM in EC biology.     
AM has potent effects on the establishment and maintenance of the EC 
barrier and is therefore a strong regulator of endothelial permeability.  Loss of EC 
barrier function is a key characteristic of acute inflammation that can proceed to 
organ dysfunction and severe infection.  AM has been shown to inhibit vascular 
leakage in response to the dramatic dysequilibrium encountered in cardiovascular 
diseases such as sepsis and inflammation [9].  Specifically, AM reduced endothelial 
hyperpermeability of HUVECs stimulated with permeability increasing agents 
including hydrogren peroxide, thrombin, E. coli hemolysin, and S. aureus α−toxins 
[9].  Further, AM has been found to effectively tighten the blood brain barrier in 
experiments utilizing cerebral ECs [55].  This endothelial stabilizing function of AM 
has been shown in vivo as well.  In rats subjected to septic shock by intravenous S. 
aureus α-toxin administration, pre-treatment with AM was able to prevent associated 
hyperpermeability of the lung, liver, ileum, and kidney [56].  Mechanistically, it has 
been suggested that AM elicits these cellular effects through increasing intracellular 
cAMP, which in turn stabilizes junctional complexes between ECs as well as 
reduces cell contraction by preventing the formation of F-actin stress fibers by 
inhibiting myosin-light chain phosphorylation (rev. [57]).  
Taken together, these data suggest that AM signaling in the blood 
vasculature contributes to its proper development, remodeling, and function. Work 
presented in this thesis demonstrates that AM signaling also plays an important role 
in the development and function of the lymphatic vascular system.  Mouse embryos 
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lacking AM or its receptors develop hypoplastic lymph sacs as a result of reduced 
proliferation of lymphatic endothelial cells (LECs) [36].  In another study contained 
within this thesis, AM was shown to inhibit VEGF-mediated increases in LEC 
permeability in vitro and in vivo [58]. 
 
AM as a Cardioprotective Factor in Vascular Smooth Muscle Cells 
  AM functions as a cardioprotective factor during hypertension.  Indeed, 
plasma levels of AM are increased in hypertensive patients and correlate with 
disease severity (Figure 1.1) [20, 59, 60].  Since hypertension can lead to impaired 
kidney function, a correlation also exists between AM plasma levels and impaired 
renal function and renal failure [60].  In patients with complications from primary 
arterial hypertension, including left ventricular hypertrophy, AM plasma levels are 
elevated as well [20].  More recently, a clinical trial showed that plasma AM has 
better prognostic value than brain natriuretic peptide (BNP) following myocardial 
infarction, therefore the clinical interest in AM during cardiovascular disease is high 
[61].  
  Perhaps the most recognized function of AM is to act as a potent 
vasodilator; with many studies finding that AM causes both a dose-dependent and 
prolonged hypotensive response in variety of tissues and species [62-67].  Up-
regulation of AM during hypertension can be cardioprotective by eliciting vasodilation 
and natriuresis, thereby reducing myocardial hypertrophy and remodeling.  For 
example, adenoviral-mediated delivery of AM significantly reduced blood pressure 
and limited cardiac and renal structural and functional damage in several rat models 
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of hypertension including the Dahl salt-sensitive model, and deoxycorticosterone 
acetate-salt model [68-70]. 
At the molecular level, AM signaling can elicit vasodilation and relaxation of 
the vascular smooth muscle  wall two ways:  i) directly through CLR activation in 
VSMCs leading to stimulation of protein kinase A (PKA) which in turn causes smooth 
muscle relaxation by opening K+ channels and activation of Ca+2 sequestration 
mechanisms or ii) indirectly through binding to CLR in ECs to initiate the secretion of 
NO which acts upon VSMC to cause relaxation (Figure 1.3) [71-73].  However, 
because the studies leading to these mechanisms utilized different species, vessels, 
and methods, the precise mechanisms responsible for the hypotensive effects of AM 
have yet to be determined [74-76]. 
To address these issues, the Caron laboratory has generated genetic mouse 
models with either haploinsufficiency or tissue-specific deletion of AM and its 
receptors.  These studies have consistently shown that while genetic reduction of 
AM or its receptor does not affect basal or stress-induced vascular tone in adult 
mice, loss of AM signaling causes reduced VSMC proliferation during embryonic 
development [34, 35, 77, 78].  The finding that AM promotes VSMC growth and 
proliferation is supported by numerous other studies [79-81].  However, the lack of a 
robust phenotype on VSMC function may be due to the modest effects resulting from 
a haploinsufficient model.  Work presented in this thesis shows that genetic deletion 
of CLR in VSMCs is compatible with survival and does not affect basal vascular 
tone, suggesting either compensation by other vasodilators or that signaling of AM 
and/or CGRP through CLR in ECs is sufficient to mediate vasodilation. 
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Research Presented in this Dissertation 
 As described in the preceding sections, AM certainly influences many aspects 
of cardiovascular physiology.  Previous studies performed in the Caron laboratory 
sought to investigate the effects of loss of AM signaling during development by 
generating gene-targeted knockout mouse models of AM, Ramp2, and Calcrl.  
These studies showed that AM signaling is essential for survival, since each of the 
genetic null mice were embryonic lethal at mid-gestation with severe defects in 
cardiovascular development [34, 35, 82].  The overall goals of this dissertation were 
to further characterize these cardiovascular defects with specific focus on the role of 
AM in both the development and function of the lymphatic vascular system and 
VSMCs.  Chapter 3 describes the discovery of a defect in LEC proliferation in mice 
globally lacking AM signaling (AM, Ramp2, Calcrl null mice) and specifically in ECs 
(EC-specific deletion of Calcrl mice).  Further, complimentary in vitro studies 
provided a mechanism for which enhanced AM signaling during the proliferation 
steps of lymphangiogenesis is necessary for proper lymphatic vascular 
development.  Chapter 4 describes an investigation into the role of AM in regulating 
lymphatic permeability in vivo and in vitro.  AM stimulation was shown to strengthen 
the LEC barrier during permeabilizing conditions by reorganizing and stabilizing 
junctional complexes.  Chapter 5 describes the generation and characterization of 
mice lacking Calcrl expression specifically in VSMCs, while maintaining normal 
expression levels in all other cell types.  These experimental mice were born at 
expected Mendalian ratios and survived to adulthood with no obvious cardiovascular 
defects when investigated for blood pressure, heart function, or metabolic function.  
11 
 
Collectively, this dissertation explores the role of AM signaling during development 
and adulthood in a cell- specific manner.          
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Figure 1.1: Fold change in plasma AM levels in a variety of human conditions.  
Bars indicate average fold change in circulating AM levels in various disease 
categories or conditions based on published human clinical data.  The horizontal line 
at 2.3 represents the average fold increase in plasma AM levels across all conditions 
(excluding sepsis). **, P < 0.007 between pregnancy and all other disease conditions 
(excluding sepsis). ##, P < 0.001 between normal pregnancy and pregnancy 
complications. *, P < 0.05 between sepsis and all other conditions.  Number on each 
bar indicates the number of published observations assessing plasma AM levels in 
each category. 
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Figure 1.2: The RAMP/Receptor paradigm for AM and CGRP signaling.  RAMPs 
convey receptor specificity by heterodimer formation with CLR in the endoplasmic 
reticulum followed by localization to the plasma membrane.  The association of CLR 
with a RAMP determines the specificity of ligand binding.  Thus, a RAMP1-CLR 
heterodimer (green) binds preferentially to CGRP, whereas association of CLR with 
either RAMP2 (dark red) or RAMP3 (light yellow) results in preferential binding to 
AM. 
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Figure 1.3: Cellular mechanisms of vasodilation induced by AM or CGRP.  AM 
binds to RAMP2/3-CLR and CGRP binds to RAMP1-CLR in ECs and VSMCs 
leading to relaxation of the VSMC wall.  In the EC-dependent pathway ,(A), ligand 
binding activates adenylate cyclase (AC) leading to the increased production of the 
second messenger cAMP which, in turn, stimulates NO synthesis and release to the 
adjacent VSMC.  NO activates guanylate cyclase (GC) that directs cGMP production 
which subsequently relaxes the VSMC by activating Ca2+ sequestration mechanism 
and opening K+ channels.  In the EC-independent pathway, (B), activation of 
receptor on VSMCs by ligands is coupled to cAMP production by adenylate cyclase.  
cAMP activates PKA which opens K+ channels and decreases intracellular 
Ca2+calcium levels, leading to VSMC relaxation.  Adapted from [83]. 
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CHAPTER 2 
THE LYMPHATIC VASCULAR SYSTEM IN DEVELOPMENT AND DISEASE: THE 
POTENTIAL FOR ADRENOMEDULLIN-BASED THERAPIES 
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The Lymphatic Vascular System & Lessons from Genetic Mouse Models 
The lymphatic vascular system works to maintain tissue fluid homeostasis, 
absorb fatty acids and lipid-soluble vitamins from the gut and traffic antigen-
presenting immune cells through the lymph nodes.  The lymphatic vasculature is a 
blind-ended network of endothelial cell lined vessels that unidirectionally transports 
tissue fluid, extravated plasma proteins, lipids and cells from the interstitial space 
back to the circulatory system via the thoracic duct into the subclavian vein.  The 
lymphatic vascular system can be divided into two distinct segments, the initial 
lymphatics and the collecting lymphatics.  The initial lymphatics are relatively small 
vessels, consisting of a single layer of endothelial cells.  They lack both a basement 
membrane and smooth muscle cell coverage.  The initial lymphatics feed into the 
collecting lymphatics, which are lined by a layer of lymphatic vascular smooth 
muscle cells and pericytes.  The collecting lymphatics generate lymph flow through 
both tonic and phasic contractions (rev. in [1]).  Recently, understanding how the 
lymphatic vascular system develops and functions has been an area of intense 
research as investigators looks to discover new avenues for treating lymphatic 
diseases. 
Florence Sabin is credited with proposing the current model of lymphatic 
vascular development over 100 years ago [2].  Through experimentation with fetal 
pigs, Sabin’s findings suggested that predetermined endothelial cells bud off from 
pre-existing veins to form primary lymph sacs, which in turn proliferate and branch 
throughout the periphery to form lymphatic vessels and capillaries.  Only recently 
has Sabin’s model gained wide acceptance due to advances in genetic engineering 
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techniques that have identified series of genes that regulate lymphatic vascular 
development in a stepwise manner (rev. in [3]).  The impact that gene targeting has 
had on driving the field forward is unparalleled, and so it is fitting that the 2007 Nobel 
Prize in Physiology or Medicine was awarded to Smithies, Capecchi and Evans in 
recognition of their efforts toward developing gene targeting approaches.   
Figure 2.1 summarizes our current understanding of the stepwise process of 
lymphangiogenesis and lists numerous genetic factors that have been identified as 
important for lymphangiogenesis through gene targeting approaches.  Development 
of the lymphatic vascular system is initiated when lymphatic-endothelial-hyaluronan-
receptor-1 (LYVE1)-expressing endothelial cells of the cardinal vein begin to express 
the transcription factor sex determining region Y-box 18 (Sox18) which drives 
expression of prospero-related homeobox 1 (Prox1) in a polarized manner [4].  
Sox18 and Prox1 transcriptionally reprogram venous endothelial cells so that they 
become specified toward a lymphatic fate.  As shown in Figure 2.2A-B, mice lacking 
either Sox18 or Prox1 are embryonic lethal at midgestation, develop with a complete 
absence of differentiated lymphatic endothelial cells (LECs), and display generalized 
interstitial edema [4, 5].   
After lymphatic endothelial competence has been established, the up-
regulation of the vascular endothelial growth factor C (VEGFC)-receptor, VEGFR3, 
in LECs confers their ability to sprout from the cardinal vein and migrate toward an 
ectopic gradient of growth-promoting VEGFC.  Vegfc null mice fail to develop a 
lymphatic vascular system and die from severe edema at e15.5  [6] (Figure 2.2C).  
More recently, mice with double genetic deletion of sprouty protein-related with 
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EVH1 domain 1 and 2 (Spred1/ 2) (negative regulators of growth factor-induced 
MAPK/ERK activation) develop marked edema, dilated lymphatic vessels and a 
hyperproliferation of LECs due to abnormal loss of VEGFC/VEGFR-3 inhibition [7] 
(Figure 2.2D).  These studies, together with work presented in this thesis, support 
an essential role for the MAPK/ERK pathway in lymphangiogenesis.   
Subsequent rounds of proliferation lead to the formation of a primary 
lymphatic plexus which is later remodeled with mural cells and luminal valves to form 
the fully functional lymphatic vascular network.  Little is known about the processes 
that regulate lymphatic vessel maturation and patterning during the later stages of 
embryonic development or during the early neonatal period. Mice lacking the 
glycoprotein podoplanin die neonatally from lymphedema as a result of severe 
lymphatic vessel disorganization, dilated vessels, and diminished lymphatic transport 
[8] (Figure 2.2E).  Mice, as well as humans, deficient for the transcription factor 
forkhead box C2 (FoxC2) have abnormal lymphatic vascular patterning, lack 
lymphatic valves, and acquire aberrant smooth muscle coverage on the initial 
lymphatics [9].  Further, mice lacking a functional PDZ domain of the ephrinB2 
protein display irregular postnatal remodeling of the lymphatic vasculature [10].  
While these data are a step forward in our understanding of this process, they do not 
describe molecular interactions responsible for proper lymphatic patterning and 
postnatal maturation.  This thesis dissertation describes an investigation into the role 
of adrenomedullin signaling through its receptor CLR in lymphatic vascular 
development, specifically during the processes of LEC proliferation after the 
formation of the primary lymph sac.     
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Diseases of the Lymphatic Vascular System 
Diseases of the lymphatic vascular system serve as an example of how lack 
of knowledge about normal and diseased tissues has limited our ability to generate 
many effective pharmacological therapies.  Failure of the lymphatic vascular system 
has devastating consequences [11].  Lymphedema is the result of inadequate 
lymphatic function and if not properly managed can lead to debilitating and painful 
limb swelling, tissue fibrosis, inflammation and increased susceptibility to infection.  
Lymphedema can be caused by rare genetically-inherited mutations resulting in 
abnormal development or function of the lymphatic vascular system either at birth, 
puberty or adulthood [12].  More common causes of lymphedema are due to 
physical disruption or damage to the lymphatic vasculature, either by surgery, 
radiation therapy or infection with the mosquito parasites Wuchereria bancrofti or 
Brugia malayi.  In industrialized countries, the occurrence of lymphedema is rapidly 
increasing, proportional to the increasing use of surgical and radiation therapies for 
life-saving cancer treatments.  Recent estimates show that one third to nearly one 
half of women develop lymphedema after breast cancer treatments [13, 14].  In 
many tropical and sub-tropical countries, parasitic filarial lymphedema or 
elephantiasis is endemic and affects approximately 120 million individuals worldwide 
[15].  Regardless of the cause, lymphedema carries with it immense psychological 
and social sequelae and disability [11]. 
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Current Therapies 
Rockson has recently provided a survey of current treatment strategies for the 
management of lymphatic vascular disease [16].  Currently, the most effective 
treatment for lymphedema consists of a multifaceted physiotherapeutic approach for 
improving lymphatic function through application of lymphatic-specific massage 
techniques, remedial exercise, fitted compression garments and skin care [16].  
Although this all-inclusive approach is largely successful among compliant patients 
[17], the daily treatments and changes in lifestyle can cause undesirable financial, 
physical and psychological strain for many patients.  
Recent surgical approaches have provided limited relief to patients with 
severe lymphedema.  For example, liposuction followed by sustained intense 
compression can relieve tissue congestion caused by collagen and fat deposition 
[18, 19].  However, liposuction only provides temporary relief from swelling and does 
not directly improve lymphatic function.  Reconstructive microsurgery through 
lymphavenous anastomoses (in effect, lymphatic bypass surgery) can provide 
minimal relief but is largely ineffective [20].  
Pharmacological therapies for lymphedema are extremely limited and largely 
controversial.  Coumarin has been shown to reduce lymphedema, but its overall 
effectiveness and functional mechanism remain controversial [21-23].  Moreover, 
long term systemic treatment with coumarin is correlated with a high rate of 
hepatotoxicity [21, 24].  Antioxidents, including selenium and flavonoids, have also 
been explored as potential therapies, but preliminary investigations into their 
effectiveness have remained inconclusive.[25]  The treatment for parasitic filarial 
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lymphedema has had better success.  Massive drug delivery programs, consisting of 
dual treatment with diethylcarbamazine and albendazole (anti-parasitic agents), can 
effectively target and eliminate infecting parasites and reduce the burden of filarial 
lymphedema in large populations [26].  However, treatment strategies for filariasis 
do not repair the previously damaged lymphatic vasculature within an individual. 
Perhaps the most exciting progress toward pharmacological treatments for 
lymphedema has come from VEGFC-based therapies.  In animal models of 
lymphedema, VEGFC-based therapies have been demonstrated to promote 
lymphangiogenesis [27-31].  Even more promising has been the recent discovery 
that adenovirally-delivered VEGFC can induce the formation of functional collecting 
lymphatics as well as improve the outcomes of lymph node transplantations in mice 
[30].  Other growth factors, including VEGFD, VEGFA, fibroblast growth factor-2 and 
hepatocyte growth factor have also shown exciting promise as therapeutic 
lymphangiogenic agents in animal models [32, 33]. Nevertheless, it remains clear 
that the identification of additional drug targets for the modulation of lymphatic 
growth or permeability is highly desirable.   
 
G-Protein Coupled Receptors as Potential Drug Targets 
Because G-protein coupled receptors (GPCRs) are pharmacologically-
tractable cell-surface receptors and are widely used for the treatment of human 
diseases, the identification of potentially useful GPCR targets for the modulation of 
lymphatic vascular growth or function would represent a major advancement in the 
field.   GPCRs are widely expressed proteins that span the cell membrane 7 times 
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and respond to a variety of stimuli including peptides, proteins, small organic 
compounds, lipids, amino acids and cations.  Recent estimates predict that humans 
have approximately 800 GPCRs which can be grouped into five major phylogenetic 
families: Rhodopsin, Secretin, Adhesion, Glutamate and Frizzled/Taste2 families 
[34].  A comprehensive review article exploring the diversity between GPCR families 
and its significance for drug design was recently published by Lagerstrom & Schioth 
[35].  In summary, GPCRs from every family are highly attractive targets for 
pharmacological manipulation by either recombinant proteins, small molecule 
compounds, allosteric ligands or antibodies.  There are currently 46 GPCRs that 
serve as drug targets for the treatment of a multitude of conditions including 
hypertension, pain, ulcers, allergies, alcoholism, obesity, glaucoma, psychotic 
disorders and HIV.  However, this leaves several hundreds of GPCRs as potential 
drug targets and among those approximately 150 are still considered orphan 
receptors (receptors for which the endogenous ligand has yet to be identified) [35].  
One major impediment to increasing the repertoire of pharmacologically useful 
GPCRs is our general lack of knowledge regarding the association of a putative 
GPCR with a precise physiological function or disease condition.   Work presented in 
this thesis describes the landmark discovery that AM signaling through the Class II 
GPCR CLR and RAMP2 oligomer represents an essential signaling pathway in 
lymphatic vascular development and function.  Moreover, these findings have the 
potential to contribute to new therapies for lymphatic vascular disease.   
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Figure 2.1: The stepwise process of lymphangiogenesis.  The development of 
the lymphatic vasculature begins with specification of lymphatic endothelial cells 
from venous precursors.  The chemoattractant and growth promoting properties of 
numerous growth factors, including VEGFC, causes lymphatic endothelial cells to 
sprout and separate from veins to form primitive lymph sacs.  Proliferation of lymph 
sacs leads to the formation of a primary lymphatic plexus which is later remodeled 
into the mature lymphatic vascular system.  Below each step is a list of genes for 
which a functional role has been demonstrated using genetically engineered mouse 
models. 
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Figure 2.2: Genetic mouse models reveal genes essential for lymphatic 
vascular development.  Generation and characterization of gene targeted knockout 
mouse models has contributed to the current model of lymphangiogenesis.  At mid-
gestation, the transcription factors (A) Sox18  and (B) Prox-1 reprograms venous 
endothelial cells of the cardinal vein in a polarized manner to become lymphatic 
precursors [4, 5].  (C) VEGFC promotes the migration and differentiation to LECs to 
form the primary lymph sac [6]. (D) Spreds 1 and 2 regulate downstream VEGFC 
signaling [7].  (E) Podoplanin promotes lymphatic vessel maturation and 
organization [8].            
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CHAPTER 3 
ADRENOMEDULLIN SIGNALING IS NECESSARY FOR MURINE LYMPHATIC 
VASCULAR DEVELOPMENT 
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Abstract 
The lymphatic vascular system mediates fluid homeostasis, immune defense 
and tumor metastasis.  Only a handful of genes are known to affect the development 
of the lymphatic vasculature and even fewer represent therapeutic targets for 
lymphatic diseases.  Adrenomedullin (AM) is a multifunctional peptide vasodilator 
that transduces its biological effects through the calcitonin receptor-like receptor 
(Calcrl) when the receptor is associated with a novel receptor activity modifying 
protein (Ramp2).  Global genetic deletion of each of these genes resulted in a 
conserved phenotypic series, providing in vivo evidence for the molecular 
components required for AM signaling during embryonic development.  Null mice 
died at mid-gestation and displayed interstitial lymphedema.  A conditional knockout 
line with loss of Calcrl in endothelial cells confirmed an essential role for AM 
signaling in vascular development.  Loss of AM signaling resulted in abnormal 
jugular lymphatic vessels due to reduction in lymphatic endothelial cell proliferation.  
Furthermore, AM caused enhanced activation of ERK signaling in lymphatic versus 
blood endothelial cells, likely due to induction of Calcrl gene expression by the 
lymphatic transcriptional regulator Prox1.  Collectively, our studies identify a new 
class of genes involved in lymphangiogenesis which represent a pharmacologically 
tractable system for the treatment of lymphedema or inhibition of tumor metastasis. 
 
 
 
 
41 
 
Introduction 
The lymphatic vascular system is an open-ended network of endothelial cell 
lined vessels that works to transport extravasated tissue fluid, proteins, metabolites 
and cells from the interstitial space back to the circulatory system via the thoracic 
duct [1].  Lymphatic capillaries, which lack a basement membrane, are made of 
overlapping endothelial cells that adhere to the extracellular matrix through fibrillin-
rich, pressure-sensing anchoring filaments.  Under conditions of interstitial edema, 
lymphatic endothelial cells stretch apart to collect excess fluid and large proteins.  
Propulsion of lymph fluid into the larger collecting lymph vessels is largely 
dependant on the vascular smooth muscle contractions of the upper circulatory 
trunks.  Lymphatic vessels also mediate lipid uptake from the gut and transport white 
blood cells and antigen-presenting cells to lymphoid organs.  Moreover, the 
lymphatic system plays important roles in pathological conditions such as 
inflammation, scarring and tumor metastasis [2-5].  Despite its central roles in both 
normal and disease physiology, our understanding of the development and 
molecular regulation of the lymphatic vascular system lags far behind that of the 
parallel blood vascular system [6, 7]. 
In recent years, advanced genetic engineering techniques have supported the 
concept that during development lymphatic endothelial cells (LECs) bud from veins 
to form primary lymph sacs which then proliferate and sprout into the periphery to 
form lymphatic capillaries and vessels.  One of the earliest molecular markers 
distinguishing venous endothelial cells with a lymphatic bias is the transcription 
factor prospero-related homeobox 1 (Prox1) [8].  Prox1 is expressed in a polarized 
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fashion in the venous endothelium and serves as a master switch for establishing 
LEC competence [9].  Knockout mice for Prox1 show ablated budding and sprouting 
of primary lymph sacs and die at embryonic day 14.5 (E14.5) with severe edema 
[10].  Genetic mouse models with loss of VEGFC signaling also develop severe 
interstitial edema due to failed lymphatic budding and migration [11].  The eventual 
separation of lymphatic vessels from the venous circulation is largely mediated by 
the tyrosine kinase Syk and adaptor protein SLP76.  Mice with homozygous 
deletions for the genes encoding these proteins develop arterio-venous shunts and 
abnormal lymphatic-venous connections [12].  Finally, several genes have been 
implicated in the later stages of lymphatic vessel patterning and postnatal 
maturation, including podoplanin [13], neuropillin2 [14], FoxC2 [15] and angiopoetin-
2 [16].  While a few of these gene products, like VEGFC and angiopoetins, show 
promise as potential targets for the stimulation, inhibition or modulation of 
lymphangiogenesis and lymphatic function in lymphedematous tissues or tumors of 
adult animals [17], there remains a crucial need to identify additional genetic and 
pharmacologically-tractable targets that regulate the development and function of 
the lymphatic vascular system [1, 18]. 
Adrenomedullin (AM) is a multifunctional 52-amino acid peptide vasodilator 
that is pathologically elevated in a variety of tumors [19] and cardiovascular 
conditions [20].  In addition to its function as a potent vasodilator, AM is also 
recognized as an important vascular factor involved in angiogenesis and endothelial 
cell proliferation.  AM treatment potently induces the proliferation, migration and 
capillary tube formation of cultured  human umbilical vein endothelial cells 
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(HUVECs) and directly promotes endothelial cell growth and survival  through 
activation of MAPK/ERK downstream signaling pathways [21-26].  Similar results 
have been recapitulated in vivo through the use of a hind-limb ischemia model [27] 
and a differentiated ES cell culture model [28] in which AM treatment promotes an 
angiogenic response.  Taken together, these data demonstrate that AM signaling in 
the blood vasculature plays an important role in vessel development, remodeling 
and function, however its role in the lymphatic vascular system has yet to be 
addressed. 
 AM binds and signals through a G-protein coupled receptor, calcitonin 
receptor-like receptor (CLR= protein; Calcrl=gene).  The ligand binding affinity of 
CLR (and other class II GPCRs) can be changed via receptor interaction with a class 
of single-pass transmembrane proteins called receptor activity modifying proteins 
(RAMPs) [29].  Since the AM receptor and the three mammalian RAMPs are highly 
expressed in the vasculature, this paradigm of cell signaling is being explored 
pharmaceutically for the potential treatment of conditions like migraine [30], 
pulmonary hypertension [31] and other cardiovascular disorders [32] and for the 
modulation of cancer progression [33].  However, determining the functional 
significance of AM signaling on the vasculature during embryogenesis and 
adulthood remains an area of intense investigation which we here address with 
genetically engineered animals that lack either AM, Calcrl or Ramp2 globally or that 
lack Calcrl specifically in endothelial cells. 
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Experimental Methods 
Animals 
The generation and characterization of mice with targeted deletions of the 
AM, Calcrl and Ramp2 genes has been described previously [34-36].  Gene 
targeting for the AM, Calcrl and Ramp2 genes was performed with targeting vectors 
and ES cells of the SvEv129/6-TC1 background.  Chimeric male mice were then 
bred to SvEv129/6-TC1 female mice in order to establish completely isogenic 
colonies.  In the case of Ramp2, we have previously reported that on the 
SvEv129/6-TC1 isogenic background there are profound fertility defects [34].  These 
fertility defects are rescued on an F1 (SvEv129/6-TC1:C57Bl6) background and so 
animals derived from F1 intercrosses were used for analysis in the current study. 
To generate CalcrlFlox/Flox mice, a Calcrl floxed targeting vector was generated 
using a 129S6/SvEv phage clone (previously described[35]) containing exons 3 
through 9 of the Calcrl gene.  LoxP sites were inserted outside of exons 5 and 6. 
The long arm of homology included exons 7, 8 and 9, while the short arm included 
exons 3 and 4.  Standard gene targeting methods were utilized to generate 
embryonic stem cells and mice with the floxed Calcrl allele.  Briefly, E14 ES cells 
were electroporated with the linearized targeting vector shown in Figure 2A.  After 
positive (G418) and negative (ganciclovir) selection 7 positive ES cell clones were 
identified from 96 selected clones.  Primers p1 and p4 were used for PCR-based 
screening of ES cells and primers p2, p3 and p4 were used for genotyping of mice 
(Figure 3.2A and Appendix: Supplemental Figure 6).  Male chimeric mice that 
transmitted the targeted allele were bred to C57BL/6J females and homozygous 
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CalcrlFlox/Flox were generated. Targeting was confirmed by Southern blotting using a 
probe indicated in Figure 2A. 
B6.Xcg-Tg (tek-cre)12Flv/J (Tie2Cre) mice were obtained from Jackson 
Laboratories.  Endothelial specific Calcrl null embryos were generated by crossing 
Calcr/+/- female mice to Tie2Cre+ male mice.  The resulting Calcrl+/-;Tie2Cre+ 
animals were then bred to CalcrlFlox/Flox  resulting in experimental animals for this 
study.   
For all studies, littermate controls were utilized.  The day of the vaginal plug 
was considered embryonic day 0.5 (E0.5). All experiments were approved by the 
Institutional Animal Care and Use Committee of The University of North Carolina at 
Chapel Hill. 
 
Antibodies and Growth Factors 
The following primary antibodies were used in this study: rat anti-mouse 
CD31(PECAM) monoclonal (BD Biosciences), rabbit anti-Prox1 (Chemicon), 
monoclonal anti-α smooth muscle actin clone 1A4 (Sigma), goat anti-mouse 
VEGFR3 (R&D Systems), Mouse anti-Phospho-ERK1/2 (p44/42) antibody 
(Thr202/Tyr204) and rabbit anti-ERK antibody (Cell Signaling Technology).  F-actin 
was stained with FITC-Phalloidin (Sigma) and nuclei were stained with Hoechst 
33258 (Sigma). 
Human AM and human AM22-52 were purchased from American Peptide, 
PD98059 from Sigma-Aldrich, and recombinant human VEGFA from Pierce 
Biotechnology. 
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In Vivo Proliferation Assay 
Pregnant females were injected intraperitoneally with 100µg/g body weight 
BrdU (Sigma, St. Louis).  After 1 hour, mice were euthanized and embryos 
recovered for immunohistochemistry as described in Appendix: Supplemental 
Methods.  BrdU positive cells were detected with the BrdU staining kit (Zymed) 
followed by staining in Mayer’s hematoxylin.  Percent proliferative cells was 
determined by blinded quantitation of BrdU positive cells in the lymphatic or vascular 
endothelium divided by total hematoxylin stained nuclei.  Data was analyzed using 
the two-tailed Student’s t-test assuming unequal variance. 
 
High Resolution, 3-D Optical Projection Tomography (OPT) 
Whole mount immunofluorescent optical projection tomography was 
performed by BIOPTONICS (Edinburg, GB) following manufacturer’s protocol.  
Briefly, E13.5 (PECAM) and E14.5 (VEGFR3) embryos were fixed in DENTS fixative 
overnight, permeablized in acetone, and washed with PBST.  Embryos were 
incubated in primary antibodies and 5% Goat serum, 1% BSA and 1% DMSO in 
PBST for 8-10 days.  Specimens were washed in multiple changes of PBST for up to 
4 days, and secondary antibodies in PBST were added.  After 8 days, embryos were 
washed in PBST followed by PBS and then imaged by BIOPTONICS OPT scanner 
3001 (MRC Technology). 
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Cell Culture 
HUVECs were obtained from Lonza (Walkersville, MD) and maintained in 
endothelial cell medium provided by the supplier and used at passages 3-7.  
HMVEC-dLys (LECs), product number #CC-2810, were purchased from Lonza and 
maintained in endothelial cell medium provided by the supplier and used at 
passages 3-7.    Culture media was changed every 2-3 days and cells were passed 
when they achieved 90% confluency. 
 
In Vitro Proliferation Assay 
Cell proliferation was measured by modified MTS assay as previously 
described [37].  Briefly, LECs and HUVECs were plated at 8 x 104 cells/ml on a 96-
well plate.  After 24h in normal growth conditions, media was changed to basic 
medium containing 0.5% FBS for 24h.  Cells were then treated with appropriate 
concentration of peptide (AM or VEGFA in replicates of 5) under low serum 
conditions for 48h at which point, 20 µl of MTS tetrazolium compound (CellTiter 
96Aquesous, Promega) was added to each well and incubation was continued for 3 
hours.  Absorbance at 490nm was recorded and background was corrected by 
subtracting the average absorbance observed in wells containing no cells. Percent 
proliferation defined as the corrected absorbance in treated samples divided by 
corrected absorbance of untreated samples. 
For total cell count determinations, LECs and HUVECs were plated at 2 x 
10^5 cells/ml in each well of 6-well plates.  After 24h in normal growth conditions, 
media was changed to basic medium containing 0.5% FBS for 24h.  Cells were then 
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treated with 10nm of AM peptide under low serum conditions for 48h.   At 48h, the 
cells were lifted off the plate by application of 0.25% Trypsin (Gibco) and counted 
visually with a hemocytometer.  Percent proliferation was a measure of treated 
samples divided by untreated samples.  Experiments were performed in duplicate 
and data is representative of 3 separate experiments. 
 
Prox1 Transfections 
For electroporation of HUVECs and LECs the plasmid pFlag, either empty or 
containing full length hProx1 [38], a kind gift from Dr. Eckard Truter, Karolinski 
Institute, Sweden, were electroporated in triplicate. 1 X 106 HUVECs or LECs were 
electroporated using the HUVEC Nucleofector kit (Amaxa). 24 hours after 
transfection RNA was generated for quantitative RT-PCR as described above. 
 
Tissue Preparation, Immunohistochemistry and Microscopy 
Tissues or cells, plated on glass coverslips, were fixed in 4% 
paraformaldehyde in PBS overnight.  For immunofluorescent staining, tissues were 
then cryoprotected with 30% sucrose in PBS overnight, embedded in OCT (Tissue-
Tek) and cryosectioned at 6-8µm.  Sections or cells were rehydrated in PBS, 
permeablized with 0.4% Triton-X100 in PBS, blocked with 4% BSA in PBS and 
incubated in primary antibody overnight.  After washing, fluorescently labeled 
secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were incubated 
for 2 hours at room temperature, sections were washed and mounted for imaging.  
EGFP was imaged immediately after permeablization.  Images were acquired on a 
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Nikon E800 microscope with a Hammamatsu ORCA-ER CCD camera using 
Metamorph Software (Molecluar Devices) and processed in Photoshop8.0 (Adobe).  
For hematoxylin and eosin staining, fixed tissues were put through an ethanol 
gradient, embedded in paraffin and sectioned at 10µm.  Sections were 
deparaffinized and stained with Mayer’s hematoxylin and eosin following standard 
protocols. 
 
Quantitative RT-PCR 
Lymphatic vessels were isolated from the hind limbs of adult SvEv129/6 mice.  
Briefly, the hind footpads of anesthetized mice were injected with 3% Chicago sky 
blue in Tyrode’s Buffer.  After incorporation, mice were euthanized and lymphatic 
vessels labeled with blue dye were excised under a dissecting microscope.  RNA 
was isolated using the RNeasy Micro kit (Qiagen, Valencia, CA) with additional 
DNAse treatment (Promega).  RNA from embryos and cultured cells was isolated 
using the RNeasy Mini kit.  cDNA was then generated using the iScript Select cDNA 
synthesis kit (Bio-Rad, Hurcules, CA). 
Quantitative PCR was performed on the Stratagene Mx-3000p machine (La 
Jolla, CA) using ABgene ROX master mix (Rochester, NY) and rodent GAPDH 
control reagents (Applied Biosystems, Foster City, CA). Relative levels of gene 
expression were determined using the comparative quantitation (∆∆CT) method with 
MxPro software (Stratagene).  Sequences for the mouse AM, Calcrl and Ramp2 
primers and probes have been published [35, 36, 39] and all other primer and probe 
sequences are provided in the Appendix.   All assays were repeated at least twice, 
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and all samples were run in triplicate. Results were analyzed using the two-tailed 
Student’s t-test assuming unequal variance. 
 
Interstitial fluid analysis 
To collect interstitial fluid from homozygous null embryos, Ramp2-/- E14.5 
embryos were dissected in PBS.  A 30.5 gauge needle was inserted under the 
edematous skin and fluid was slowly drained.  Rat lymph was collected directly from 
the thoracic duct of an adult Sprague-Dawley rat and mouse serum was collected by 
tail bleed from adult SvEv129/6 mice. Samples were centrifuged at 30,000x g and 
supernatants were loaded onto 8-12% gradient polyacrlymide tris-glycine gels.  Gels 
were stained with coomassie blue 250 (Sigma). 
 
Quantification of Lymph Sac Area  
Hematoxylin and eosin stained transverse sections of the jugular region of AM, 
Calcrl and Ramp2 null embryos were imaged on a Leica MZ16 dissecting 
microscope.  Sections containing jugular lymph sacs that were matched for the 
same anteroposterior level were blindly measured using ImageJ software (NIH, 
USA).  In order to normalize for section variability, the area of the lymph sac (defined 
as the area within the perimeter) was divided by the area of the adjacent jugular 
vein. 
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Transmission Electron Microscopy 
Embryos were collected and fixed in 2% formaldehyde/2.5% glutaraldehyde 
in 0.15M sodium phosphate buffer, pH 7.4, overnight at 4˚C. Following several 
washes in sodium phosphate buffer, the samples were post-fixed for 1 hour in 
potassium ferrocyanide-reduced osmium, dehydrated through a graded series of 
ethanol and embedded in PolyBed 812 epoxy resin (Polysciences, Warrington, PA). 
Using a diamond knife, 1 µm cross-sections were cut, stained with 1% toluidine blue 
and examined by light microscopy to isolate areas containing jugular lymph sacs. 
Ultrathin sections were cut with a diamond knife (70-80 nm thickness), mounted on 
200 mesh copper grids and stained with 4% aqueous uranyl acetate for 15 minutes 
followed by Reynolds’ lead citrate for 8 minutes. The sections were observed using a 
LEO EM-910 transmission electron microscope (LEO Electron Microscopy, Inc., 
Thornwood, NY), accelerating voltage of 80 kV, and micrographs were taken using a 
Gatan Orius SC 1000 CCD Camera (Gatan, Inc., Pleasanton, CA). 
 
In Cell Western 
8x104 cells/ml were cultured under normal growth conditions and after 24 
hours media was changed to basic medium containing 0.5% FBS for 24 hours.  
Cells were then treated with 10nm AM for indicated times.  At the end of incubation, 
the medium was removed and the cells were fixed, permeabilized, blocked, and 
treated with the appropriate antibodies per manufacturer’s instructions (LI-COR).  
The primary antibodies, anti-phosph-ERK1/2 and anti-ERK1/2, were used at 
52 
 
dilutions 1:100 and 1:25, respectively, and detected with goat-anti-mouse IR680 and 
goat-anti-rabbit IR800 each at 1:5000 dilutions.  The plates were scanned with the 
Odyssey infrared scanner, data was obtained using scanner software and total area 
under the curve was determined by Gaussian best-fit analysis. 
 
Western Blotting 
LECs were treated with 10nm AM for indicated time points, washed three 
times with PBS, lysed in 100µl of sample buffer, boiled for 10 min, loaded onto a 
10% polyacrylimide gel and resolved by SDS-PAGE.  Protein was then transferred 
to a polyvinylidene diflouride (PVDF) membrane which was subsequently blocked in 
5% non-fat dry milk overnight at 4 degrees. The primary antibodies were incubated 
overnight at 4 degrees at 1 mg/ml and detected with secondary antibodies as 
described for the In Cell Western above.  The blot was imaged with the Odyssey 
infrared scanner and data was obtained using scanner software. 
 
Results 
The RAMP2-CLR complex is the functional AM receptor during embryonic 
development. 
AM-/-, Calcrl-/- and Ramp2-/- embryos failed to survive and developed severe 
interstitial edema without hemorrhage by mid-gestation (Figure 3.1A,D,G).  
Histology of the AM-/-, Calcrl-/- and Ramp2-/- embryos confirms the presence of 
extreme interstitial edema and the notable absence of hemorrhagic plaques (Figure 
3.1B,C;E,F;H,I).  The onset of edema between the different lines was temporally 
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staggered by approximately 24 hours, after which all null embryos were found dead 
1-2 days later.  The delay in phenotypic onset in Ramp2-/- embryos suggests that 
some compensatory signaling for AM, perhaps through a RAMP3-CLR complex, 
may still exist during embryonic development.  However, our previous observations 
that RAMP3 null mice survive to adulthood with few phenotypic defects [34] 
demonstrates that RAMP3 is unable to fully replenish RAMP2-mediated AM 
signaling in vivo.  Moreover, we found that Ramp2-/- embryos displayed remarkably 
similar developmental defects to those we have previously described for AM-/- and 
Calcrl-/- mice [35, 36] (Appendix: Supplementary Figure 1).  Therefore, this 
conserved phenotypic series from three independent knockout mouse lines provides 
compelling genetic evidence to define CLR and RAMP2 as the receptor components 
required for AM signaling during embryogenesis.  
 
Absence of AM signaling results in generalized interstitial edema and 
embryonic lethality. 
Generalized edema and mid-gestation lethality can be caused by a multitude 
of developmental defects during embryogenesis.  To determine whether the loss of 
AM signaling in vascular endothelial cells could account for the embryonic edema 
and/or lethality of global AM-/-, Calcrl-/- and Ramp2-/- embryos, we generated mice 
with a conditional allele for the Calcrl gene.  Using the Cre-LoxP gene targeting 
strategy, we generated homozygous “floxed” mice for the Calcrl gene and confirmed 
correct gene targeting by Southern blot and genomic PCR (Figure 3.2A-C).  
Importantly, our gene targeting approach ensured that the loxP sites flanked the 
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same genomic regions as those deleted in the original Calcrl knockout mouse [35], 
thereby eliminating the possibility of generating allelic phenotypes.  Homozygous 
floxed Calcrl mice (CalcrlFlox/Flox) appeared normal, bred well and had levels of Calcrl 
gene expression that were indistinguishable from wildtype animals (Figure 3.2D). 
As shown in the schematic of Figure 3.2E, we bred the CalcrlFlox/Flox  mice to 
mice that were heterozygous for the Calcrl gene knockout and positive for 
expression of Cre recombinase in endothelial cells via expression of a Tie2-Cre 
transgene [40].  By breeding onto a Calcrl+/- genetic background we ensured robust 
excision of a single floxed allele and thereby reduced the incidence of mosaic 
cellular excision.  Importantly, Calcrl+/- mice are born at the expected Mendelian ratio 
and survive to adulthood with few phenotypic defects [34].   The resulting mice from 
the Cre-LoxP breeding strategy, CalcrlLoxP/-;Tie2Cre+, were therefore global 
heterozygotes for Calcrl and were lacking Calcrl expression specifically in 
endothelial cells as early as E10.5.  We noticed a slight reduction in the Mendelian 
distribution of CalcrlFloxP/-;Tie2Cre- mice (Figure 3.2F) which is consistent with the 
leakiness of the Tie2-Cre transgene in the female germline leading to global Calcrl 
excision and embryonic lethality [40].   Consistently, the CalcrlLoxP/-;Tie2Cre+ mice 
were embryonic lethal and developed extreme interstitial edema without 
hemorrhage, sometimes as early as E13.5 (Figure 3.2F,G).  However, in contrast to 
the global Calcrl-/- mice which die by E13.5, the onset of edema and eventual demise 
of the CalcrlLoxP/-;Tie2Cre+  mice was often substantially delayed to ~E16.5, three to 
four days later than the global Calcrl-/- mice.  Thus, we conclude that endothelial-
specific deletion of Calcrl prolonged the survival of AM signaling mutants during 
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development, but nevertheless resulted in similar generalized edema without 
hemorrhage compared to the global Calcrl knockout mice.  These data demonstrate 
that the cellular basis of the embryonic edema and eventual lethality in AM signaling 
mutant mice is due to loss of AM signaling in endothelial cells. 
 
AM signaling is activated during lymphangiogenesis. 
Despite the well-established role for AM in maintaining vascular permeability 
[41, 42], we very rarely observed blood hemorrhage and only occasionally in 
embryos that were visibly deteriorated or near death.  For example, out of 72 
wildtype embryos, 7 (9.7%) exhibited some form of visible hemorrhage and only 4 
out of 56 Ramp2-/- littermates (7.1%) showed evidence of hemorrhage.  Thus, the 
remarkable lack of embryonic hemorrhage in the AM-/-, Calcrl-/- and Ramp2-/- 
embryos suggested to us that the developing blood vasculature remained largely 
intact during embryonic development.  Moreover, presence of high MW proteins in 
the interstitial fluid confirmed that the null mice suffered from embryonic 
lymphedema as opposed to osmotic imbalance (Appendix: Supplementary Figure 
2).  Thus, based on the absence of blood hemorrhage, the presence of embryonic 
lymphedema and the fact that the edematous phenotype of AM signaling null mice 
more closely resembled that of other mouse models with defects in 
lymphangiogenesis [10, 11, 14] rather than defects in blood vascular permeability 
[43-46] we hypothesized that AM signaling might be principally important for 
orchestrating normal lymphangiogenesis. 
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First, we demonstrated that AM, Calcrl and Ramp2 are expressed in adult 
lymphatic vessels at levels similar to those observed in whole embryonic RNA 
extracts (Figure 3.3A).  To determine if AM, was also expressed in lymphatic 
vessels during embryonic development, we made use of an enhanced green 
fluorescent protein (EGFP) that was inserted at the initiator methionine of the 
endogenous AM gene by homologous recombination and serves as a biological 
marker of AM gene expression in AM+/- and AM-/- mice [36].  As shown in Figure 
3.3B, AM was expressed in endothelial cells lining the jugular vein and budding 
lymph sac at E12.5, which correlates with the earliest stages of lymphatic vascular 
development.  Interestingly, we noticed that the pattern of AM expression in the 
jugular vein was often polarized towards the developing lymph sac, similar in pattern 
to that of the master transcriptional regulator of lymphatic specification, Prox1 [9].  
We therefore conclude that the expression of genes required for AM signaling is 
robust in adult and developing lymphatic endothelial cells (LECs) and is similar in 
pattern to that of Prox1 during embryogenesis. 
We next performed immunohistochemistry using LEC markers to determine if 
AM signaling was required for the initial formation of jugular lymph sacs.  Distinct 
lymph sacs were present in wildtype, Ramp2-/- and AM-/- embryos by E13.5 (Figure 
3.4A-C) and stained positively for PECAM and the lymphatic specific makers 
VEGFR3 and Prox1, indicating normal lymphatic differentiation from venous 
vasculature. Similar results were observed in Calcrl-/-  embryos (data not shown).  
We also identified distinct VEGFR3-positive vessels in the skin of Ramp2-/- embryos 
(Figure 3.4D,E), indicating that the development of the dermal lymphatic vasculature 
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remains intact in AM signaling mutant mice.  From these findings, we conclude that 
AM signaling is not required for the early stages of lymphangiogenesis, including 
differentiation and migration of LECs and the formation of primary lymph sacs and 
dermal lymphatic vessels. 
 
AM signaling regulates lymphatic endothelial proliferation.   
Although immunohistochemistry revealed the presence of lymph sacs in the 
AM signaling null mouse models, we noticed from histological sections that the 
jugular lymph sacs appeared strikingly smaller than those of litter-matched wildtype 
embryos (Figure 3.5A-D).  To confirm the apparently hypoplastic lymph sacs, we 
used computerized morphometry to calculate lymph sac area and found that all null 
mice showed significantly reduced lymph sac area compared to wildtype embryos at 
E13.5 (Figure 3.5E-G). Thus, despite excessive interstitial lymphedema (which 
would normally cause lymphatic vessel distension), the lymph sacs of the AM 
signaling null embryos remained significantly smaller than wildtype lymph sacs, 
suggesting either a functional failure of the early lymphatics to take up extravasated 
fluid or an abnormality in LEC growth and proliferation. 
To determine whether an ultrastructural defect in LECs could lead to a 
functional failure of lymphatic vessels during development, we performed 
transmission electron microscopy of Ramp2-/- and wildtype mice at E14.5. LECs of 
the jugular lymphatic vessels in wildtype mice displayed typical features including 
overlapping cell-cell contacts (Figure 3.6A, arrowheads), electron-dense tight 
junctions (Figure 3.6B,C, arrows) and anchoring filaments (Figure 3.6A).  Wildtype 
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lymphatic vessels at this stage of development also lacked a basement membrane 
and lymphatic smooth muscle cells (see also Appendix: Supplemental Figure 3), 
thus precluding the possibility that failure of smooth muscle recruitment could 
account for the lymphatic phenotypes observed in the AM signaling null mice.  In 
Ramp2-/- mice the overlapping cell-cell contacts, tight junctions and anchoring 
filaments remained intact (Figure 3.6D, E).  Occasionally, necrotic LECs were 
observed in Ramp2-/- mice (Figure 3.6F), but the tight junctions nevertheless 
remained intact.  Consistently, we found that Ramp2-/- LECs appeared markedly 
thinner than wildtype LECs.  Based on these data, we found no substantial evidence 
to suggest that the lymphatic vasculature of the Ramp2-/- mice would fail to function 
due to ultrastructral abnormalities. 
To determine whether the smaller lymph sacs of AM signaling mutant mice 
could be due to abnormal endothelial cell proliferation, we used a BrdU incorporation 
assay to count proliferating cells in both lymph sacs and adjoining jugular veins.  In 
AM-/-, Ramp2-/- and Calcrl-/- embryos, there were significantly fewer proliferative 
endothelial cells in the lymph sacs, while the proliferation of the venous endothelial 
cells, although somewhat reduced in the null mice, never reached statistical 
significance (Figure 3.7A,B,C).  Taken together these results demonstrate that lack 
of AM signaling during embryonic development leads to a specific reduction of 
lymphatic, but not venous, endothelial cell proliferation. 
To confirm that loss of AM signaling preferentially affected the development of 
the lymphatic versus blood vascular system, we used whole mount 
immunohistochemistry for VEGFR3 or PECAM followed by 3-dimensional optical 
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projection tomography [47] in Ramp2-/- mice.  While we found no obvious differences 
in the morphological development of the blood vascular system between wildtype 
and knockout mice (Figure 3.7D,E), we did observe extraordinary differences in the 
jugular lymphatic trunks (Figure 3.7F,G, large white arrows).  While wildtype mice 
had large, well-formed jugular lymphatic trunks, the same vessels were essentially 
absent in the Ramp2-/- littermates (Figure 3.7 and Appendix: Supplemental 
Movies 4 & 5).  Notably, the retroperitoneal lymph vessel (which develops into the 
thoracic duct) and the dermal lymphatic vessels of Ramp2-/- embryos appeared 
indistinguishable from those of wildtype littermates (Figure 3.7, small yellow arrows 
and Figure 3.4D,E).  Therefore, we conclude that AM signaling is preferentially 
required for the normal proliferation and morphological integrity of the jugular 
lymphatic vessels during the later stages of lymphangiogenesis. 
 
AM signaling is enhanced in lymphatic endothelial cells. 
To determine the downstream signaling cascades that are associated with the 
enhanced activity of AM signaling in LEC proliferation, we made use of two distinct 
endothelial cell lines; human umbilical vein endothelial cells (HUVECs) and human 
dermal lymphatic microvascular endothelial cells (HMVEC-dLy, herein referred to as 
LECs).  Histology and immunocytochemistry of the LEC cell line demonstrated 
different cellular morphology and the expression of Prox1 compared to HUVECs, 
which are consistent with the characterization of these cells as lymphatic endothelial 
cells (Figure 3.8A).  Stimulation of HUVECs and LECs with vascular endothelial cell 
growth factor A (VEGFA) resulted in an expected and dose-dependant increase in 
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cellular proliferation that did not differ significantly between the two cell lines (Figure 
3.8B).  In contrast, while AM elicited a modest yet significant increase in HUVEC 
proliferation, the proliferative effects of AM on LECs were substantially more robust 
and significantly different than the effects of AM on HUVEC proliferation at 10nM 
(Figure 3.8C).  Direct cell count determinations verified that LECs treated with 10nM 
AM for 48 hours showed two-fold more proliferation than similarly treated HUVECs 
(81% vs. 37% more than control, p<0.01, data not shown). 
To determine the downstream signaling pathways associated with the effects 
of AM signaling on LEC proliferation, we quantitatively assessed the activation of 
ERK in HUVECs and LECs that were treated with 10nM AM.  Using a Gaussian fit-
curve analysis, we found that AM stimulation of LECs resulted in approximately 
twice the overall levels of phosphorylated ERK over a 30 minute time course 
compared to HUVECs (Figure 3.8D).  Inhibition of AM-mediated ERK 
phosphorylation by a RAMP2-specific AM inhibitor, AM22-52 [48], and by the MAPK 
inhibitor, PD98057, confirmed that ERK activation by AM signaling in LECs is 
mediated through a RAMP2-CLR receptor complex (Figure 3.8E).  Taken together, 
these comparative studies in cultured endothelial cells demonstrate that AM 
signaling, through a RAMP2-CLR receptor complex, has a preferential and 
enhanced effect on ERK-mediated LEC proliferation compared to HUVECs. 
Several comparative transcriptional profiling studies have shown enhanced 
expression of AM signaling genes in lymphatic versus blood endothelial cells [49, 50] 
and lymphedematous versus normal vasculature [51].  Therefore, we hypothesized 
that the enhanced sensitivity of LECs to AM signaling could be due to preferential 
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up-regulation of the receptor components required for AM signaling.  Quantitative 
RT-PCR for AM, Calcrl and Ramp2 confirmed our assumptions and showed 
approximately 4 times higher levels of gene expression in cultured LECs compared 
to HUVECs (Figure 3.9A).  Because we had previously observed that the 
expression of AM in vivo closely matched the pattern of Prox1 expression in the 
developing lymphatic sacs of E13.5 embryos (Figure 3.3B), we next wanted to 
determine whether the AM receptor, Calcrl, could be a downstream target gene of 
Prox1. Therefore, we transfected a hProx1 expression plasmid into cultured LECs 
and measured mRNA production of enodgenous LYVE and Calcrl.  Consistent with 
previous studies showing that Prox1 is not required for the lymphatic-specific 
expression of LYVE [10], over-expression of Prox1 in LECs did not induce the 
expression of LYVE (Figure 3.9B).  In contrast, over-expression of Prox1 resulted in 
a 3-fold increase in endogenous Calcrl expression levels compared to empty vector 
control transfections (Figure 3.9C).  We therefore conclude that the expression of 
genes required for AM signaling is preferentially robust in LECs compared to 
HUVECs and furthermore inducible by Prox1. 
 
Discussion 
We have performed a comparative phenotypic characterization of three 
independent gene knockout models for genes that encode proteins purported to be 
involved in signaling for AM peptide.  The remarkable conservation in phenotypes 
between knockout mice with targeted loss of either AM peptide, the GPCR receptor 
CLR or its modifying protein, RAMP2 provides compelling genetic evidence to define 
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the receptor components required for AM signaling during embryogenesis.  The 
paradigm of RAMP-GPCR signaling offers the exciting opportunity to generate 
pharmacological compounds that specifically interact at the RAMP-GPCR interface 
for modulating the activity of several peptide agonists.  As an example, the small 
molecule compound BIBN4096BS [52] specifically binds to RAMP1-CLR complexes 
to antagonize CGRP activity and is currently in clinical trials for treatment of migraine 
[53].  Our conserved phenotypic series of null mouse models suggest that 
compounds specific to the RAMP2-CLR interface would provide the best 
pharmacological target for modulation of AM activity in vivo. 
AM is a secreted peptide vasodilator that is highly expressed in blood 
endothelial cells and induced by hypoxia to promote angiogenesis and inhibit 
vascular permeability [31, 54].  Here we show that AM and its receptors are more 
highly expressed in LECs under the control of the lymphatic-specific transcriptional 
regulator Prox1.  Therefore, the enhanced level of CLR receptor expression 
disposes LECs to a more robust AM response than blood endothelial cells (Figure 
3.10).  As a consequence, global genetic loss of either AM, Calcrl or Ramp2 causes 
marked and preferential reduction in the proliferation of lymphatic endothelial cells of 
the jugular lymphatic vessels.  Our current explanation for the cause of edema in 
these mouse models is that lack of lymphatic proliferative signals during 
lymphangiogenesis results in smaller, lower capacity jugular lymphatic vessels that 
are unable to accommodate the normal uptake of extravasated fluid and thus 
exacerbates massive interstitial edema.  It is also worth emphasizing that the precise 
cause of embryonic lethality has yet to be determined. 
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A multitude of developmental defects during embryogenesis can lead to 
edema and mid-gestation lethality.  For example, we cannot at this time exclude the 
possibility that global loss of AM signaling might also cause excessive permeability 
of the blood vasculature, contributing to the overall hydrops phenotype.  In this 
regard, our data suggest that global loss of either AM, Calcrl or Ramp2 results in thin 
vascular smooth muscle coverage of large blood vessels [35, 36] (Appendix: 
Supplementary Figure 1E-F).   However, based on the absence of hemorrhage 
and the remarkable similarity of our phenotype to other genetically engineered 
mouse models with defects in lymphangiogenensis [10, 11, 14] (rather than mouse 
models with leaky blood vasculature or thin vascular smooth muscle walls [43-46]), 
we contend that the major contribution to the overall hydrops phenotype in AM 
signaling null mice comes from the loss of gene function in the lymphatic 
vasculature.  We have also shown that global loss of either AM, Calcrl or Ramp2 
results in smaller hearts with thin compact zones and ventricular trabeculae [35, 36] 
(Appendix: Supplementary Figure 1 A-D), and heart failure can sometimes 
contribute to embryonic edema.  However, since the AM signaling null mice do not 
suffer from hepatic congestion or bradycardia and since the edema is 
characteristically “generalized interstitial edema” (as opposed to pericardial effusion 
which most often accompanies embryonic heart failure) we feel it is unlikely that 
heart failure is the principle cause of embryonic edema. 
Our generation and characterization of mice with conditional loss of Calcrl in 
vascular endothelial cells further supports our interpretation for a principal and 
essential role for AM signaling in endothelial cells during embryonic development.  
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Since expression of the Tie2-Cre transgene precedes the onset of 
lymphangiogenesis in embryonic veins and since the Tie2 promoter is active in 
developing lymphatic endothelial cells [55], it is likely that excision of the Calcrl gene 
also occurs robustly in the developing LECs of the CalcrlLoxP/-;Tie2Cre+ mice.  
However, the Tie2-Cre transgene is also expressed in cells of the hematopoietic 
lineage, which have modest expression of AM signaling components [56, 57] and 
have been previously demonstrated to contribute to lymphatic vascular development 
[58].  Therefore, we cannot exclude the possibility that loss of AM signaling in the 
hematopoietic lineage also contributes to the overall phenotype of the CalcrlLoxP/-
;Tie2Cre+ mice.  Similarly, we cannot exclude the possibility that loss of AM 
signaling in cardiac structures derived from Tie2-Cre expressing progenitors (for 
example, mesenchymal cells of the atrioventricular canal and the proximal outflow 
tract) may contribute to the phenotype.  Future studies with conditional deletion of 
the Calcrl gene exclusively in BECs, LECs or hematopoietic cells will help address 
these caveats, but suitable Cre transgenic mouse lines with exclusive expression of 
Cre in these cell types must first be generated. 
Hypoplastic growth of the lymphatic vasculature during development has also 
been described in mice that lack neuropillin2 [14], a co-receptor for the 
lymphangiogenic growth factor VEGFC.  One assumption that can be made from 
these apparently similar phenotypes is that VEGFC and AM signaling may interact 
simultaneously to control the proliferation of the developing lymphatic vessels during 
embryogenesis.  However, in contrast to the AM signaling null phenotype, loss of 
neuropillin2 selectively and transiently compromised the proliferation of smaller 
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lymphatic vessels and capillaries, but not jugular lymphatic vessels, during 
development.  Together, these results demonstrate that the development of small 
and large lymphatic vessel populations is under the control of different 
lymphangiogenic factors and that these growth factors may work autonomously in 
lymphatic vessels that arise from different progenitor populations. 
Our current study and those of others [21-26] show that AM signaling directly 
promotes endothelial cell growth and survival  through activation of MAPK/ERK 
downstream signaling pathways.  In contrast, the Sprouty/Spred family of proteins 
mediates an important negative regulation of growth factor- and cytokine-induced 
MAPK/ERK activation.  Recently, Taniguchi et al showed that mice with double 
genetic deletion of Spred 1 and 2 develop marked edema and dilated, blood-filled 
lymphatic vessels [59].  While the number of blood vessels and blood endothelial 
cells in Spred-1/2 deficient embryos did not differ from wildtype, the authors found a 
significant increase in the number of LECs and lymphatic vessels which was due to 
abnormal loss of VEGFC/VEGFR-3 inhibition and subsequent higher ERK activation.  
The phenotype of hyperplastic lymphatic vascular growth by enhanced ERK 
activation in Spred-1/2 knockout mice stands in notable contrast to our AM signaling 
null phenotype of hypolastic lymphatic vascular growth caused by decreased ERK 
activation in LECs.   Taken together, the comparative findings from the two studies 
are entirely consistent with the notion that the tight control of ERK activation by 
vascular growth factors is essential for the controlled proliferation of LECs during 
development. 
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Failure or insufficient function of the lymphatic vascular system results in 
disfiguring, disabling and sometimes life-threatening swelling of the limbs, called 
lymphedema [60] which most often occurs as a result of a parasitic filarial infection 
or secondary to surgical removal of lymph nodes, radiation therapy or infection [2].  
Recent studies have also brought the lymphatic system to the forefront as an 
important route of tumor metastasis [3, 6], the major cause for treatment failure and 
decreased survival in cancer patients.  Thus, a concerted effort is being made to 
identify new genetic and/or pharmacological targets for the management and 
treatment of lymphedema and for inhibiting the metastatic spread of cancer cells.  
Ideally, these treatments would improve lymphatic permeability, induce the 
controlled proliferation of the existing lymphatic vasculature or inhibit tumor 
lymphangiogenesis.  The elucidation of a previously unrecognized role for AM 
signaling in orchestrating embryonic lymphangiogenesis considerably expands our 
understanding of the relatively small repertoire of molecular regulators controlling 
this process.  Moreover, the conserved phenotypic series of mice is the first genetic, 
in vivo data confirming that Ramp2 interaction with Calcrl is required for AM 
signaling during embryonic development.  Therefore, further characterization of AM 
signaling and its pharmacological modulation via RAMP2-CLR effectors might lead 
to novel therapeutic strategies for the treatment of lymphedema or inhibition of tumor 
metastasis. 
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Figure 3.1: Phenotypic series of AM signaling null mice.  Genetic deletion of 
genes responsible for AM signaling results in a phenotypic series of null mice with 
generalized edema and lethality at mid-gestation. Generalized interstitial edema, 
without hemorrhage, is observed throughout Calcrl-/- embryos at E12.5 (A). Similar 
edema is present by E13.5 in AM-/- embryos (D) and by E14.5 in Ramp2-/- embryos 
(G).  Edema was not observed one day before onset and no viable embryos were 
ever recovered 1-2 days after edema onset.    H&E stained transverse sections of 
wildtype littermates (B, E, H) and Calcrl-/-, AM-/-, and Ramp2-/- (C, F, I) embryos at 
E12.5, E13.5 and E14.5, respectively.  Arrowheads indicate interstitial fluid 
accumulation. 
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Figure 3.2:  Generation and characterization of conditional Calcrl line.  (A)  
Schematic diagram depicting strategy used for generation of a “Floxed” Calcrl allele 
by gene targeting.  The top figure shows the endogenous wildtype Calcrl allele.  The 
targeting vector was designed so that LoxP sites would flank the same exons that 
were deleted in the Calcrl global knockout [35].  The third line depicts the targeted 
CalcrlFlox allele and the fourth line depicts the CalcrlLoxP allele after Cre-mediated 
excision.  Primers used for isolation of correctly targeted ES cells and for routine 
genotyping are shown with small arrows.  (B) Correctly targeted ES cells were 
confirmed by Southern blot analysis using the probe depicted in Fig. 2A.  (C) PCR 
genotyping for the CalcrlFlox allele.  (D) Quantitative RT-PCR was performed on RNA 
isolated from lungs and hearts of wildtype and homozygous CalcrlFlox/Flox  mice and 
revealed no significant differences in the expression of the CalcrlLoxP allele before 
Cre-mediated excision.  (E) Schematic representation of breeding scheme used to 
generate mice with Calcrl expression deleted specifically in endothelial cells by use 
of the Tie2Cre transgene.  (F) Results of cross demonstrate that no viable CalcrlLoxP/-
;Tie2Cre+ mice were found beyond E16.5.  (G) Compared to CalcrlLoxP/+;Tie2Cre+  
control littermates, the CalcrlLoxP/-;Tie2Cre+ mice displayed remarkable hydrops 
without hemorrhage which phenocopied the global Calcrl knockout phenotype, yet 
often occurred substantially later at E16.5. 
 
70 
 
 
 
Figure 3.3:  AM signaling components are expressed in adult and developing 
lymphatic vessels.  (A) Isolated adult lymphatic vessels express AM, Calcrl and 
Ramp2 at levels similar to whole embryo RNA extracts.  Adult mouse lymphatic 
vessels were identified by the uptake of Evan’s blue dye injected into the hind paw 
and were subsequently microdissected for RNA isolation.  Expression of AM, Calcrl 
and Ramp2 mRNAs in these vessels was comparable to mRNA levels in E10-E12.5 
embryos by quantitative RT-PCR. n>4 samples, analyzed twice in triplicate.  (B) To 
determine whether lymphatic endothelial cells (LECs) express AM during 
development, we made use of an enhanced green fluorescent protein that serves as 
a biological marker of AM gene expression in AM gene targeted mice[36].  Unstained 
transverse sections through the jugular region of an E12.5 AM+/- embryo show that 
AM is expressed in endothelial cells of both the jugular vein (V) and jugular lymph 
sac (LS) (arrows).  Note the polarized expression of AM in the progenitor cells which 
will eventually migrate to form the lymph sac. 
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Figure 3.4:  Differentiated lymph sacs and dermal lymphatics are present in 
AM signaling null embryos.  Immunofluorescent staining of transverse sections 
through the jugular region (A-C) and sagittal sections through the skin (D-E) of 
E13.5 embryos.  (A) Endothelial cells of lymph sacs (LS) from wildtype (WT) mice at 
E13.5 express VEGFR3 (red) and Prox1 (green).  (B) Similar staining is observed in 
the lymph sacs of Ramp2-/- littermates.  Nuclei stained with Hoechst are indicated in 
blue (A,B).  (C) Prox1 (green) is also correctly co-expressed with PECAM (red) in 
lymph sacs of AM-/- embryos.  (D-E) Dermal lymphatics (arrows) are present in WT 
(D) and Ramp2-/- (E) littermates at E14.5 as shown by VEGFR3 staining (red) and 
PECAM (green). Dermal blood endothelium (arrowheads) expresses PECAM, but 
not VEGFR3. n>6 embryos per genotype. (Carotid artery, A; Jugular vein, V; lymph 
sac, LS; Skin, S) 
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Figure 3.5: Loss of AM signaling results in hypoplastic lymph sacs.  Lymph 
sacs of Calcrl-/-, AM-/-, and Ramp2-/- embryos are significantly smaller than those of 
their WT littermates at E13.5. (A-D) H&E stained sections through trasverse sections 
of the jugular lymph sacs (LS) of WT (A), Calcrl-/- (B), AM-/- (C), and Ramp2-/- (D) 
embryos at E13.5.  Note the remarkable decrease in size of lymph sacs relative to 
jugular vein (V) and carotid artery (A) in the AM signaling mutant embryos, despite 
massive interstitial edema. (E-G) Quantitation of lymph sac area, normalized to 
jugular vein area in Calcrl-/-(E), AM-/-(F), and Ramp2-/- (G) embryos (black bars) and 
their WT littermates (grey bars) at E13.5.  Panels E, F and G have different scales.  
n>6 embryos per genotype.  Carotid artery, A; Jugular vein, V; lymph sac, LS.  Error 
bars indicate SEM. p-values are from student’s t-test. 
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Figure 3.6: Lymphatic endothelial cells of Ramp2-/-  mice are thin with 
otherwise normal ultrastructural features.   Transmission electron microscopy of 
WT (A-C) and Ramp2-/- (D-F) lymph sacs at E14.5.  In general, the LECs of Ramp2-/- 
mice appeared significantly thinner than those of wildtype littermates.  Although 
obvious edema was present in the interstitial space surrounding both the veins and 
lymph sacs in Ramp2-/-embryos, endothelial cells could be followed continuously 
around both vessel types, without obvious breaks or gaps.  Other typical 
ultrastructual features of lymphatic vessels were identified in both wildtype and 
Ramp2-/- mice including: overlapping contacts (arrowheads), tight junctions (arrows) 
and anchoring filaments (a).  Occasionally necrotic endothelial cells (**) were 
observed in Ramp2-/- mice, but the associated tight junctions remained structurally 
intact.  n=2 wildype and 3 Ramp2-/- . L; lumen.  Bar equals 1µm. 
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Figure 3.7: AM signaling is required for the proliferation and growth of jugular 
lymphatic vessels during embryonic development.  (A-C) The percentage of 
proliferating cells to total cells was determined in the jugular vein and neighboring 
jugular lymph sac of WT (grey bars) and Calcrl-/-, AM-/-, and Ramp2-/- (black bars, A-
C respectively) littermate embryos.  Percent proliferative cells was defined as the 
number of BrdU positive endothelial cells divided by total number of endothelial cells 
in each vessel. Error bars indicate SEM. *, p values were generated by student’s t-
test and were p = 0.01 for Calcrl-/- (A), p = 0.004 for AM-/- (B), and p = 0.01 for 
Ramp2-/- (C).  n>6 animals per genotype.  (D-E)  Whole mount immunofluorescence 
of developing vasculature identified by PECAM staining and visualized by 3-D 
optical projection tomography of wildtype (D) and Ramp2-/- (E) littermate embryos at 
E13.5.  (F-G)  Whole mount immunofluorescence of developing lymphatic 
vasculature identified by VEGFR3 staining and visualized by 3-D optical projection 
tomography of wildtype (F) and Ramp2-/- (G) littermate embryos at E14.5.  Compare 
the presence of well-formed jugular lymph sacs in the wildtype embryo (yellow 
arrows in F) to the relative lack of jugular lymphatic vessels in the Ramp2-/- littermate 
(G).  Note that the retroperitoneal lymph vessel (red arrows) and dermal lymphatic 
vessels (green asterisk) of Ramp2-/- mice appear normal compared to those of 
wildtype embryos.  3 embryos from 2 different litters were stained for PECAM and 
VEGFR3.   The Appendix contains online links to movies for enhanced, high 
resolution, 3-dimensional viewing (Appendix: Supplemental Movies 4 & 5). 
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Figure 3.8:  AM signaling preferentially mediates enhanced ERK activation in 
LECs compared to HUVECs.   (A) Cultured LECs and HUVECs are 
morphologically and genetically distinct cell lines based on histology and expression 
pattern of Prox1.  (B)  Stimulation of HUVECs and LECs with the potent growth 
factor VEFGA resulted in a dose-dependant increase in cell proliferation that was not 
significantly different between the two cell lines.  Data represent averages of 4 
independent experiments, each performed in duplicate.  (C) Stimulation of HUVECs 
and LECs with AM peptide resulted in a dose-dependant increase in cell proliferation 
that was significantly greater in LECs compared to HUVECs. * p<0.05  Data 
represent averages of 4 independent experiments, each performed in duplicate.  (D) 
Stimulation of HUVECs and LECs with 10nM AM peptide resulted in a significantly 
greater induction of ERK phosphorylation in LECs compared to HUVECs over a 30 
minute time course. * p<0.03 at 15 and 20 minute time points.  Data represent 
averages of 3 independent experiments, each performed in duplicate.  (E)  Induction 
of ERK activation by AM stimulation in LECs was significantly reduced by the 
RAMP2-specific peptide inhibitor, AM22-52, and completely blocked by the MAPK 
inhibitor PD98057.  *p<0.05 compared to untreated; **p<0.05 compared to AM 
treated.  Data represent averages of 3 independent experiments, each performed in 
duplicate. 
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Figure 3.9:  AM signaling genes are preferentially up-regulated in LECs via 
Prox1 induction.  (A) Comparative gene expression analysis for hAM, hCALCRL 
and hRAMP2 in cultured HUVECs versus LECs, demonstrating significantly higher 
levels of gene expression in LECs compared to HUVECs.  Data represent averages 
of 3 independent experiments, each performed in duplicate. (B)  As expected, the 
endogenous expression of the lymphatic-specific marker LYVE was not induced by 
transient overexpression of hProx1 in LECs.  (C)  In contrast, expression of 
endogenous Calcrl was potently induced by transient overexpression of hProx1 in 
LECs.  Data presented in C and D are from one experiment and representative of 3 
independent transfections each performed in triplicate. 
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Figure 3.10:  Model for role of AM signaling in lymphangiogenesis.  Preferential 
up-regulation of AM signaling genes in lymphatic endothelial cells leads to robust 
AM signaling and enhanced activation of ERK phosphorylation in lymphatic versus 
blood endothelial cells which is essential for maintaining normal lymphatic vessel 
proliferation from E14.5 to birth. 
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ADRENOMEDULLIN STABILIZES THE LYMPHATIC ENDOTHELIAL BARRIER IN 
VITRO AND IN VIVO 
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Abstract 
 The lymphatic vascular system functions to maintain fluid homeostasis by 
removing fluid from the interstitial space and returning it to venous circulation.  This 
process is dependent upon the maintenance and modulation of a semi-permeable 
barrier between lymphatic endothelial cells of the lymphatic capillaries.  However, 
our understanding of the lymphatic endothelial barrier and the molecular 
mechanisms that govern its function remains limited.  Adrenomedullin (AM) is a 52 
amino acid secreted peptide which has a wide range of effects on cardiovascular 
physiology and is required for the normal development of the lymphatic vascular 
system.  Here, we report that AM can also modulate lymphatic permeability in 
cultured dermal microlymphatic endothelial cells (HMVEC-dLy).  AM stimulation 
caused a reorganization of the tight junction protein ZO-1 and the adherens protein 
VE-cadherin at the plasma membrane, effectively tightening the endothelial barrier.  
Stabilization of the lymphatic endothelial barrier by AM occurred independently of 
changes in junctional protein gene expression and AM-/- endothelial cells showed no 
differences in the gene expression of junctional proteins compared to wildtype 
endothelial cells.  Nevertheless, local administration of AM in the mouse tail 
decreased the rate of lymph uptake from the interstitial space into the lymphatic 
capillaries.  Together, these data reveal a previously unrecognized role for AM in 
controlling lymphatic endothelial permeability and lymphatic flow through 
reorganization of junctional proteins. 
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Introduction 
 The lymphatic vascular system is a blind-ended network of endothelial cell 
lined vessels that functions to maintain fluid homeostasis by unidirectionally 
transporting tissue fluid, extravasated plasma proteins, lipids, and cells from the 
interstitium to the circulatory system by way of the thoracic duct.  When the 
lymphatic vascular system fails to function properly patients are at risk of developing 
serious and debilitating lymphedema.  Pressure sensing, fibrillin-rich anchoring 
filaments that tether lymphatic endothelial cells (LECs) to the extracellular matrix 
contract in response to increases in interstitial pressure, thereby stretching LECs 
apart and facilitating lymph uptake into lymphatic capillaries.  However, recent 
evidence suggests that LECs are also active participants in lymph transport through 
formation of an endothelial barrier that can regulate both ion and protein transport [1-
3].  While these studies have implicated vascular endothelial growth factors A and C 
(VEGFA, VEGFC) and the intracellular signaling molecule cAMP as potential players 
in LEC permeability regulation, there remains a need to identify pharmacologically 
tractable targets that can efficiently modulate lymphatic permeability.  
 Adrenomedullin (AM) is a highly conserved 52 amino acid peptide vasodilator 
that is upregulated in a variety of cardiovascular conditions [4-6].  First recognized 
for its ability to maintain vascular smooth muscle tone, AM is also an important 
regulator of endothelial cell biology.  For example, numerous in vitro studies have 
shown that AM is a potent angiogenic factor [7-9].  Our own recent studies using 
knockout mice have revealed that AM and its receptors are required for normal 
lymphatic vascular development [10].  
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 With regard to endothelial permeability, AM treatment of human umbilical vein 
endothelial cell (HUVEC) monolayers dose dependently reduced hyperpermeability 
caused by inflammatory mediators including H2O2, thrombin, E. coli hemolysin and 
S. aureus α-toxin [11-13]  The protective effect of AM on the endothelial barrier has 
also been shown in vivo in rat ileum exposed to S. aureus α-toxin and ex vivo in 
rabbit lungs exposed to H2O2 [11, 13].  Further, in the blood-brain barrier, several 
studies have shown that AM treatment increased transendothelial electrical 
resistance thereby reducing endothelial permeability [14-16].  Taken together, these 
data suggest AM functions as a potent factor in maintaining the blood endothelial 
barrier; however, whether this function is conserved in LECs and to what extent 
remains unknown. 
 The purpose of this study was to explore the role of AM in the regulation of 
lymphatic permeability.  We evaluated the effects of AM on the expression and 
localization of LEC junction components.  Specifically, the response to AM treatment 
of the tight junction molecules Zonulus Occludin (ZO-1), Claudin-5, Claudin-12, and 
Junction Adhesion Molecular C (JAMC) as well as the endothelial-specific adherens 
protein VE-cadherin were assessed.  Further, the ability of AM to modulate LEC 
permeability was measured utilizing both in vitro and in vivo approaches.  The in vivo 
studies exploited the technique of fluorescent tail microlymphography and provided 
functional validation of our in vitro observations.   Together, these data establish a 
previously unrecognized role of AM in stabilizing of the endothelial barrier and 
modulating lymphatic flow in vivo. 
 
89 
 
Experimental Methods 
Cell Culture 
 Cryopreserved adult human dermal lymphatic microvascular endothelial cells 
(HMVEC-dLys) were obtained from Cambrex (Walkersville, MD) and maintained in 
Clonetics (East Rutherford, NJ)  microvascular endothelial growth medium (EGM-
2MV) and endothelial basal medium (EBM), respectively.  Human AM and human 
AM 22-52 were purchased from American Peptide (Sunnyvale, CA), Forskolin from 
Sigma-Aldrich, and recombinant human VEGFA from Pierce Biotechnology.  Goat 
anti-VE-cadherin (C-19) antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  Mouse anti-ZO-1 antibody (33-9100) was obtained from Zymed 
(San Francisco, CA).  Cy2 and Cy3-labeled secondary antibodies were from 
Jackson Immunoresearch (West Grove, PA).   
 
Immunofluorescence labeling and microscopy 
 For ZO-1 and VE-cadherin localization, cells were grown on 0.2% gelatin 
coated coverslips until they achieved confluence.  The medium was changed to 
serum-free conditions and the cells were stimulated with AM (100 nM), VEGFA (10 
ng/mL) or vehicle (0.1% BSA) for 30 min.  The cells were then washed twice with 
PBS with calcium and then fixed/permeabilized in ice-cold ethanol for 30 min.  Cells 
were blocked with 3% BSA in PBS for 1 h at RT and incubated with primary antibody 
in 3% BSA overnight at 4°C and with appropriate seco ndary antibody for 1 h at RT.  
Nuclei were labeled with Hoechst 33258 (Sigma).  The coverslips were mounted on 
glass slides and images were obtained with a Nikon E800 microscope with a 
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Hammamatsu ORCA-ER CCD camera using Metamorph Software (Molecular 
Devices) and processed in Adobe Photoshop 8.0 (Adobe).    
 
Endothelial cell permeability 
 HMVEC-dLys permeability was studied as previously described [17-19].  
Briefly, cells were plated at a density of 1 x 105 cells/cm2 on gelatin-coated 
membranes (Corning Costar Transwells, 0.4 µm pore size, 6.5 mm diameter) and 
medium was changed every 24 h.  Permeability of monolayers was measured in 
terms of Trypan Blue-BSA (TB-BSA) transfer [17].  At 96 h post seeding, 
membranes were incubated with test ligands in HBSS containing 0.03 M HEPES 
(HBSS/HEPES) in both the apical and basal-lateral chambers.  In the apical 
chamber, 4% TB-BSA was added with or without test ligands followed by gentle 
shaking at 37°C/5% CO 2 under sterile conditions for 90 min.  At the end of the 
incubation, samples were taken from the lower chamber and the absorbance at 
590nm was measured.  The relative permeability was calculated by dividing the OD 
of treated samples by vehicle control. 
 
Gene Expression Analysis 
 Total RNA was isolated from cells using the Qiagen RNAEasy Mini Kit and 
DNase Treated with Promega DNase per manufactures instructions.  RNA was 
reverse transcribed using MMV reverse transcriptase (Invitrogen).  cDNA was used 
for semi-quantitative RT-PCR or quantitative RT-PCR using gene-specific primers, 
SYBR Green (Stratagene), and the Stratagene MXP3000 and MxPro Software 
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(Stratagene).  The following murine primers sequences were used:  VE-Cadherin: 
Forward: 5’-GGTGGCCAAAGACCCTGAC-3’ Reverse: 5’-
ACTGGTCTTGCGGATGGAGT-3’, JAMC: Forward: 5’-
GCTGGGAGAGCACATGCAA-3’ Reverse: 5’-CAGGAGCTCTGGGCTCACA-3’.   
Primers sequences for ZO-1, Claudin-5 and Claudin-12 were designed by the report 
by Holmes et al [20].  The following human primers sequences were used: VE-
Cadherin: Forward: 5’-GCCAGGTATGAGATCGTGGT-3’ Reverse: 5’-
GTGTCTTCAGGCACGACAAA-3.  Primer sets for human ZO-1, Claudin-5, Claudin-
12, and JAMC were purchased from Qiagen. 
 
Isolation of AM-/- Endothelial Cells 
 The generation and characterization of mice with targeted deletion of the Adm 
gene has been previously described [21].  To isolate AM-/- endothelial cells, timed 
matings were established between AM+/- mice and embryos were harvested at 
embryonic day 13.5.  Genotyping was performed as previously described [21] on 
genomic DNA isolated from yolk sacs.  Whole embryos were treated with enzyme 
solution containing 2.4U/mL Neutral Protease and 150U/mL Collagenase Type II 
(Worthington Biochemical) at 37˚C for 30 minutes to generate a single cell 
suspension.  Cells were incubated with 3 µg Rat anti-Mouse CD31 (BD Pharmigen) 
at 4˚C for 30 minutes and then washed 3 times.  The cells were then incubated with 
Sheep anti-Rat IgG Dynabeads (Invitrogen) at 4˚C for 20 minutes and then washed 
4 times.  Bead-bound cells were collected for RNA purification and levels of gene 
expression for junctional proteins were determined as described above.    
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Quantitative Tail Microlymphography 
 The flow velocity of the dermal lymphatic vessels in the mouse tail was 
measured as previously described [22].  Briefly, adult male 129S6/SvEv mice were 
anesthetized by subcutaneous injection of avertin at a concentration of 0.5mg/gm 
body weight.  Mice placed on a heating pad in the working space underneath a Leica 
MZ 16 FA dissecting microscope.  The tail was immobilized on the pad with two-
sided tape.  Next, 1 µL of a 25% FITC-Dextran (2,000,000 kDa) with vehicle or AM 
peptide [10 ng/µL] was loaded into a microsyringe (Hamilton, Reno, NV) fitted with a 
30-gauge needle and was injected intradermally at the tip of the mouse tail.  The 
flow of FITC-Dextran through the dermal lymphatics was acquired with a camera 
fitted onto the Leica microscope every minute for 15 minutes.  Flow rates were 
determined using offline image analysis (Adobe Photoshop 8.0 and Image J) and 
application of a stepwise polynomial equation [22].  The data for each subregion 
were fit to this equation with a least squares nonlinear regression algorithm.  All 
animal procedures were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill. 
 
Statistics       
 Results are represented as ± S.E.M.  Statistical analyses were performed 
with a Student t test with unequal variance.  A P value of <.05 was considered 
statistically significant.  
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Results 
AM prevents VEGFA-mediated increase in lymphatic endothelial cell 
permeability. 
 HMVEC-dLys were grown to a monolayer in transwells and paracellular 
permeability was measured by the ability of Trypan Blue-labeled bovine serum 
albumin (TB-BSA) to pass through a monolayer from the apical chamber to the basal 
lateral chamber in the presence or absence of AM or VEGFA [19].  Treatment with 
AM did not change the basal permeability of the HMVEC-dLy monolayer compared 
to vehicle control (Figure 4.1).  As expected, treatment with VEGFA resulted in a 
significant increase in permeability across the HMVEC-dLys monolayer.  AM 
stimulation of LECs in the presence of VEGFA dose-dependently prevented the 
VEGFA-induced increase in permeability of the HMVEC-dLys monolayer to albumin.  
Therefore, although AM did not affect LEC permeability under basal conditions, it 
was highly effective at counteracting the permeabilizing effects of VEGFA on 
cultured LECs.  
 
AM stabilizes lymphatic endothelial cell-cell junctions.   
 HMVEC-dLys were grown to confluence and then treated with vehicle control, 
AM, VEGFA, or the combination of AM with VEGFA.   Vehicle treated HMVEC-dLys 
displayed a mosaic pattern of ZO-1 and VE-cadherin staining that was characterized 
by both continuous and discontinuous patches along the cell-cell membranes 
(Figure 4.2A and 4.2E).  Treatment of HMVEC-dLys with AM resulted in the 
formation of continuous tight junction strands as indicated by the tight junction 
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protein ZO-1 (Figure 4.2B).  Further, AM caused a reorganization of VE-cadherin at 
the plasma membrane which appeared as a linearized adherence junction band 
compared to vehicle treated cells (Figure 4.2F).  As expected, treatment with 
VEGFA dramatically disrupted of both ZO-1 and VE-cadherin localization, indicated 
by gaps and an intermittent, zipper-like staining pattern (Figures 4.2C and 4.2G).  
Surprisingly, co-treatment of AM with VEGFA completely abrogated the VEGFA 
induced disruption ZO-1 and VE-cadherin localization at the plasma membrane 
(Figure 4.2D and 4.2H).  We also noticed that AM treatment appeared to only affect 
the localization of ZO-1 and VE-cadherin, but not the total amount of protein present 
at the cellular junctions.  These data demonstrate that AM functions to reorganize 
LEC paracellular junctions by forming a tighter paracellular seal between cells and 
preventing their disruption by permeabilizing agents such as VEGFA.  
 
AM stimulation does not change the expression of junction genes at the RNA 
level.  
 RNA was isolated from LECs treated with AM or with vehicle control and gene 
expression was measured by quantitative RT-PCR.  There was no significant 
difference in the expression of ZO-1, Claudin-5, Claudin-12, JAMC, or VE-cadherin 
between AM treated and vehicle control (Figure 4.3).  Therefore, the effects of AM 
on LEC junction composition are independent of changes in gene expression, 
suggesting that modulation of lymphatic function by AM is likely to occur rapidly in 
vivo. 
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Genetic depletion of AM does not change the expression of junction genes at 
the RNA level.   
 To determine whether a genetic reduction in AM could influence the 
expression of junction genes in vivo, we isolated endothelial cells from AM-/- mice at 
embryonic day 13.5.  Although somewhat reduced, the gene expression levels of 
ZO-1, Claudin-5, Claudin-12, JAMC and VE-cadherin were not statistically different 
in AM-/- endothelial cells compared to endothelial cells isolated from wildtype 
littermate controls (Figure 4.4).  Therefore, even though AM-/- mice die at mid-
gestation with vascular defects, the loss of AM in endothelial cells does not affect the 
expression of genes important for endothelial barrier function.       
 
AM reduces lymphatic flow in vivo.   
 To address whether the permeability effect of AM on LECs could result in 
altered lymphatic flow in vivo we used fluorescent tail microlymphography in adult 
male mice.  Like in humans, lymphography of the mouse tail provides a sensitive 
and quantitative measure of dermal lymphatic capillary flow that is largely 
independent of the extrinsic effects of blood flow on lymphatic function.  Briefly, 
FITC-dextran in the presence or absence of AM was injected into the interstitial 
space of the mouse tail, and the ability of the dextran to enter the lymphatic 
capillaries was monitored over time.  Consistent with previously published results 
from other groups [22-24], the basal lymphatic flow rates in the wild-type SvEV129/6 
mouse tail was 0.78 mm/min (Figure 4.5).  When AM was co-administered with the 
FITC-dextran, we consistently found a significant decrease in lymphatic flow rates, 
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with an average uptake rate of 0.52 mm/min.  Moreover, co-administration of AM 
with VEGFA was able to completely inhibit VEGFA-mediated increases in lymphatic 
permeability.  Therefore, these data demonstrate that AM can potently reduce 
lymphatic flow rates in vivo.  
 
Discussion 
 In the present study, we demonstrate that AM stabilizes the barrier function of 
LECs both in vitro and in vivo.  AM dose-dependently prevented VEGFA-mediated 
increases in permeability of cultured HMVEC-dLys to albumin.  Molecularly, AM 
treatment reorganized ZO-1 and VE-cadherin at the plasma membrane to form 
continuous cell-cell contacts, thereby limiting paracellular transport.  In addition, we 
showed that exogenous AM peptide effectively slowed lymphatic flow rates in the 
mouse tail basally and in the presence of VEGFA.  Importantly, the ability of AM to 
modulate lymphatic barrier functions was independent of changes in gene 
expression of tight junction and adherens junction components both in vitro and in a 
genetic knockout mouse model. 
  Previous studies have shown that AM can stabilize the endothelial barrier of 
various blood vascular beds during inflammatory conditions (H2O2, thrombin, S. 
aureus α-toxin, E. coli. Hemolysin) and thus presumably reduce edema formation [9, 
11-13].  However in another study, AM increased inflammatory edema accumulation 
caused by substance P and bradykinin [25].  Although these studies were not able to 
separate the direct anti-inflammatory functions of AM from its effects on vascular 
permeability, our study sheds new light of the in vivo functions of AM in vascular 
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beds that contain both blood and lymphatic capillaries.  We found that the ability of 
AM to maintain barrier function is not limited to blood endothelial cells but also 
affects LECs.  Because lymphatic uptake was significantly reduced after co-
administration of AM in vivo, our results suggest an essential role for AM in 
perpetuating inflammatory edema. 
  The VEGF family members VEGFA and VEGFC have both been shown to 
modulate lymphatic permeability.  Targeted overexpression of VEGFA in the mouse 
epidermis exacerbated lymphatic leakage after acute UVB irradiation [3], while 
polymorphisms in the VEGFA promoter region leading to enhanced VEGFA 
expression have been attributed to hydrocele development in lymphatic filariasis [2].  
In addition, VEGFC has been demonstrated to reduce the transendothelial electrical 
resistance (TEER) of a LEC monolayer [1].  While both VEGFA and VEGFC 
increase lymphatic permeability, AM represents one of the first angiogenic factors 
that can stabilize the lymphatic endothelial barrier.  Therefore, the local interactions 
between VEGF family members and AM in regulating blood and lymphatic 
microcirculation warrant additional investigation. 
  We have previously shown that AM and its receptors are essential for the 
development and function of the lymphatic vasculature [10].  AM transduces its 
signal through a G-protein coupled receptor, calcitonin receptor-like receptor (CLR= 
protein; Calcrl=gene) when the receptor is associated with receptor activity 
modifying protein 2 (RAMP2) [26].   Mice that have targeted deletions of the genes 
that encode for either AM, CLR, or RAMP2 die at mid-gestation with generalized 
edema that is characterized by diminished proliferation of LECs [10].  A conditional 
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knockout of Calcrl in endothelial cells using the Cre-LoxP homologous 
recombination system also resulted in a similar phenotype, supporting an essential 
function for AM signaling in endothelial cells [10].   Our studies, and those of others 
[27, 28], have shown that AM and its receptors are intrinsically enriched in LECs 
compared to blood vascular endothelial cells.  Therefore, the enhanced sensitivity of 
LECs to local AM provides an explanation, in part, for the remarkable phenotype of 
the null mice.  Our current study extends our understanding of AM function in LECs 
and suggests that an additional factor leading to the embryonic edema of the null 
mice may be leaky, hyperpermeable lymphatic capillaries that are unable to support 
lymphatic flow in vivo.  Consistent with findings from other groups [9, 16], the fact 
that isolated endothelial cells lacking AM had normal expression of genes encoding 
junctional proteins further demonstrates that the effects of AM on the endothelial cell 
barrier are largely mediated by structural reorganization of the plasma membrane 
rather than changes in gene expression.    
  The unique molecular interface formed between the association of CLR with 
RAMPs provides a distinctive target for pharmacological drug design.  In fact, two 
compounds that target the CLR-RAMP1 interface are currently in clinical trials for the 
treatment of migraine pain associated with calcitonin gene related peptide biology 
[29-32].  Our current study suggests that modulation of AM activity through small 
molecule targeting of the CLR-RAMP2 complex could provide an effective means of 
altering lymphatic permeability for either the treatment of lymphedema or the 
inhibition of tumor metastasis through the lymphatic vasculature.   
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Figure 4.1:  Effects of AM on the permeability of HMVEC-dLy monolayers.   
Cells were treated with 0.1% BSA alone, AM (100 nM), VEGFA (10 ng/mL), or 
VEGFA with increasing concentrations of AM (0.1 nM-100 nM) for 90 min.  Relative 
changes in permeability were determined by measuring TB-BSA transfer for each 
treatment normalized to vehicle. control.  #P<0.01 compared to vehicle control.  
*P<0.01 compared to VEGFA treated.  Data represented as mean +/- SEM from 3 
independent experiments, each performed in triplicate. 
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Figure 4.2:  AM stabilized the endothelial barrier in HMVEC-dLys in the 
presence of VEGFA.  Treatment with 0.1% BSA (Veh.) showed intact monolayer as 
visualized by ZO-1 (A) and VE-cadherin (E).  Stimulation with 100 nM AM resulted in 
linearization of both ZO-1 (B) and VE-cadherin (F) at the cell-cell junction.  VEGFA 
(10 ng/mL) treated cells displayed discontinued ZO-1 (C) and VE-cadherin staining 
(G).  Co-treatment of AM with VEGFA stabilized ZO-1 (D) and VE-cadherin (H); 
completely preventing VEGFA-mediated barrier disruption.  Original magnification 
400X.  Each image is representative of each experimental condition imaged from 4 
separate fields repeated 3 times in triplicate. 
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Figure 4.3:  Stimulation of HMVEC-dLys with AM does not affect gene 
expression of junction components.  Total RNA was isolated from HMVEC-dLys 
treated with 0.1% BSA or 100 nM AM and the gene expression of ZO-1, Claudin-5, 
Claudin-12, JAMC, and VE-cadherin were assessed relative to GAPDH.  No 
statistical significant differences were found between the two groups suggesting the 
effect of AM on barrier function is independent to changes in gene expression of 
junction components.  n>3 with each assay performed in duplicate. 
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Figure 4.4:  Genetic loss of AM does not affect gene expression of junction 
components in vivo.  Using magnetic bead purification, endothelial cells were 
isolated from AM-/- and wildtype littermate embryos at embryonic day 13.5.  The 
gene expression of ZO-1, Claudin-5, Claudin-12, JAMC, and VE-cadherin were 
determined and normalized to their expression in whole embryo.  Although AM-/- 
endothelial cells had somewhat diminished gene expression levels, there were no 
statistically significant differences compared to wildtype endothelial cells.  n>3 with 
each assay performed in duplicate. 
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Figure 4.5:  AM decreases lymph uptake into the lymphatic capillaries in the 
mouse tail.  Tails of SvEv129/6 wildtype mice were injected with 200 kDa FITC-
Dextran and movement of the labeled-dye into the lymphatic capillaries was 
measured over time.  The rate of uptake in the absence of AM (100nm) was 
0.78mm/min while the rate of uptake in the presence of AM was significantly 
decreased to 0.52mm/min.  Co-treatment of AM with VEGFA (1.0µM) completely 
abrogated VEGFA mediated increase in lymphatic permeability.  P*<0.01 to Veh. 
P<0.01 to VEGFA treated.  n>4 for each treatment group. 
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Abstract 
Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP), two 
members of calcitonin peptide family, are secreted peptides that play important roles 
in the development, function, and maintenance of the cardiovascular system.  During 
several cardiovascular stresses like hypertension, renal failure, and myocardial 
infarction, AM and CGRP plasma levels are robustly increased, suggesting a 
cardioprotective homeostatic role.  Specifically, the vasodilatory activities of AM and 
CGRP may function to counteract the arterial vasoconstriction in hypertensive 
patients.   
The 7-transmembrane G-protein coupled receptor calcitonin receptor-like 
receptor (CLR=protein name, Calcrl=gene name) is highly expressed in vascular 
smooth muscle cells (VSMCs) and endothelial cells (ECs) and mediates the cellular 
effects of both AM and CGRP.  We have previously shown that global deletion of 
Calcrl results in embryonic lethality, thereby precluding the ability to study the effects 
of Calcrl deletion during adult cardiovascular disease.  To overcome the embryonic 
lethality and provide an animal model in which the role of AM and CGRP in VSMCs 
could be studied, VSMC-specific Calcrl knockout mice were generated.  VSMC-
specific Calcrl knockout mice were born at expected Mendelian ratios with no 
obvious developmental defects.  We found no significant difference in basal blood 
pressure or cardiac function in VSMC-specific knockout mice compared to controls.  
Unexpectedly, response to phenylephrine-induced vasoconstriction was blunted in 
knockout mice.  Together, these data demonstrate that Calcrl expression in VSMCs 
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is not required for embryonic survival or maintaining basal vascular tone and 
suggests that other hemodynamic mechanisms may compensate for loss of Calcrl.    
 
Introduction 
Calcitonin receptor-like receptor (CLR=protein name, Calcrl=gene name) is a 
receptor for two potent vasodilator peptides, adrenomedullin (AM) and calcitonin 
gene-related peptide (CGRP).  Downstream signaling pathways for AM and/or 
CGRP signaling vary in both intracellular pathways and physiological effects, 
dependent upon the tissue type [1].  However, in most tissues, including vascular 
smooth muscle cells (VSMCs), the signaling cascade is most likely initially mediated 
by coupling of CLR to Gsα, activation of adenylate cyclase, and subsequent 
production of the second messenger cAMP to orchestrate downstream effectors 
(rev. in [2]).   
CLR is a seven-transmembrane GPCR and a member of the family of Class II 
GPCRs which, among others, includes calcitonin receptor (CTR), PTH 1 and 2 
receptors, and VPAC1 [3, 4].  Like other Class II GPCRs, the binding specificity of 
CLR is dictated by the formation of a heterodimer with a family of single-pass 
transmembrane proteins called receptor affinity modifying proteins (RAMPs) [5].  In 
this non-classical signaling paradigm, the RAMP1-CLR heterodimer functions as the 
receptor for CGRP while the RAMP2 or RAMP3-CLR complex constitutes an AM 
receptor [6].  AM signaling through RAMP2-CLR is essential for survival since mice 
with genetic deletions of AM, Ramp2, or Calcrl all encounter embryonic lethality with 
severe cardiovascular defects [7-9].  In contrast, mice lacking CGRP signaling 
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through CLR by gene targeted deletion of RAMP1 survive to adulthood. [10],Li M in 
preparation 2009].  Together, these data suggest that signaling through CLR can 
lead to divergent downstream effects that are ligand and RAMP dependent. 
CLR is highly expressed in the tissues of the cardiovascular system including 
the vasculature, lungs, and heart [11, 12].  Signaling through CLR in each of these 
tissues is essential for proper development of the cardiovascular system since mice 
with targeted deletion of Calcrl die during mid-gestation with thinner VSMC walls, 
hypoplastic lymph sacs, and disorganized hearts [8, 9].  In adulthood, activation of 
CLR by either AM or CGRP functions to maintain homeostasis by counteracting 
increases in blood pressure by causing a potent and long lasting relaxation of the 
VSMC layer wall [13-16].  Notably, during cardiovascular stresses that result in 
changes in blood pressures (including pregnancy, sepsis, congestive heart failure, 
hypertension, and kidney failure) plasma levels of both AM and CGRP are elevated, 
suggesting that signaling of these peptides through CLR plays a homeostatic role in 
the cardiovascular system (rev. in [2, 17]).     
Studies exploring the mechanism by which CLR mediates its hypotensive 
responses are complex and profoundly affected by the method and dose of agonist 
administration as well as the tissue bed and species examined [13, 18-22].  Agonist 
binding to CLR relaxes vascular smooth muscle tone in two ways:  i) directly through 
CLR activation on VSMCs leading to activation of cAMP and PKA, which in turn 
causes opening of K+ channels and activation of Ca2+ sequestration mechanisms 
or ii) indirectly through activation of CLR on ECs to initiate secretion of nitric oxide 
(NO), which acts upon VSMC to cause relaxation [23-25].  However, determining 
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which of these pathways is most important for mediating the hypotensive response 
remains unclear [26-28].   
The purpose of this study was to examine the role of CLR signaling in 
vascular smooth muscle cell development and function.  Specifically, we aimed to 
more clearly define role of CLR in vasorelaxation and hypotension.   To achieve 
these goals, we used the Cre-LoxP system to generate VSMC-specific Calcrl null 
mice, thereby eliminating signaling for both AM and CGRP in VSMCs.  All mice were 
born at the expected Mendelian ratios and survived well into to adulthood, 
demonstrating that expression of Calcrl in VSMCs in not required for normal 
embryonic development or survival.  Furthermore, we found no significant 
differences in basal vascular tone or cardiac function between knockout and control 
mice.  Interestingly, knockout mice displayed a decreased vasodilatory response to 
phenylephrine compared to control mice, suggesting that compensatory 
mechanisms may be in place to adjust to lack of AM and CGRP signaling in VSMCs.  
 
Experimental Methods 
Animals 
The generation of CalcrlFlox/Flox mice has been previously described and were 
maintained on the C57B/6 genetic background  [9].  C57BL/6 x SJL-Tg(Tagln-
cre)1Her (SM22-Cre) mice were obtained from the Jackson Laboratory [29].  
Vascular smooth muscle- specific Calcrl-null animals were generated by crossing 
CalcrlFlox/Flox with heterozygous SM22Cre+ mice (Calcrl+/+ x SM22Cre+).  The 
resulting male Calcrl+/LoxP;SM22Cre+ mice were bred to female CalcrlFlox/Flox mice, 
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generating the experimental (CalcrlLoxP/LoxP;SM22Cre+) and control 
(Calcrl+/LoxP;SM22Cre+) littermate mice used for this study.  All mice used for this 
study were 3-4 month old male mice on a mixed genetic background.  PCR 
genotyping was performed using genomic toe DNA to verify the Cre-mediated 
recombination of floxed Calcrl allele.  Primer sets were used to detect the SM22Cre 
transgene, the Calcrl allele, and the recombined Calcrl floxed allele as previously 
described [9, 29]. 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill. 
 
Gene Expression Analysis 
 To verify that the Cre-mediated excision event of the Calcrl floxed allele 
specifically down-regulated expression of Calcrl in vascular smooth muscle cells, 
RNA was isolated from tissues of experimental and control mice including the aorta, 
heart, bladder, and skeletal muscle.  Because the expression of Calcrl is very high in 
endothelial cells (ECs), prior to RNA isolation, the advential and endothelial layers of 
the aorta were removed by enzymatic digestion with Type 2 collegenase 
(Worthington Biochemical Corporation) to obtain purified VSMC as previously 
described [30].  cDNA was made using Invitrogen MMLV reverse transcriptase and 
RT-PCR was performed with following primers and probe was used:  Calcrl Forward: 
5'-CAAGATCATGACGGCTCAATA-3'; Calcrl Reverse: 5'-
CGTCATTCCAGCATAGCCAT-3'; Calcrl internal probe: 5'-FAM-
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CATGCAGGACCCCATTCAACAAGCAT-TAMRA-3'.  Calcrl gene expression was 
normalized to rodent GAPDH expression (Applied Biosystems) Cat#4308313).         
 
Blood Pressure Measurements 
Heart rates and blood pressures were measured on unanesthetized mice by 
the Hatteras Instruments computerized tail cuff system [31].  For drug studies, intra-
arterial catheter measurements were taken as previously described [32].  Briefly, 
mice were anesthetized with 1-1.5% isoflurane and placed on a heating pad to 
maintain body temperature at 37°C.  Catheters were i nserted into the right carotid 
artery and the left jugular vein.  Baseline blood pressure was established before 
each drug was administered and allowed to re-establish before the next drug was 
administered.  Phenylephrine (Sigma) was delivered at 30, 60, or 90µg/kg in 50µl 
saline.  Maximal change in blood pressure response was measured and in all 
treatments baseline blood pressure was re-established within 2 min.   
 
Echocardiography   
Transthoracic echocardiography (TTE) was performed on 3-4 month old male 
mice at baseline using a 30-MHz probe and Vevo 660 Ultrasonography 
(VisualSonices).  Mice were anesthetized with 1-1.5% isoflurane.  Body temperature 
was maintained at 37°C by placing mice under a heating  lamp and heart rate was 
closely monitored.  The heart was imaged in the two-dimensional mode in the 
parasternal long-axis view.   Measurements were obtained by positioning an M-
mode curser perpendicular to the interventriculuar septum and the posterior wall of 
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the left ventricle at the level of the papillary muscle. All measurements were acquired 
and analyzed according to the American Society of Echocardiography guidelines 
[33]. 
 
Histology 
Hearts were dissected with the corresponding ascending aorta and fixed in 
4% paraformaldehyde and 6-10 µm sections were prepared.  The sections were 
stained with H&E to assess gross morphology of the heart.  Cell thickness of the 
VSMC layer of the thoracic aorta was measured.  To measure heart-to-body ratios, 
mice were weighed and the hearts were dissected, washed with PBS, separated into 
the 4 chambers, and weighed.   
 
Metabolic Assessment 
 Mice were contained in metabolic cages for 3 days with free access to food 
and water.  At each 24 time point urine volume, water consumption, and mouse 
weight was measured. 
 
Statistics 
 Results are represented as ± S.E.M.  Statistical analyses were performed 
with a Student t test with unequal variance.  A P value of <0.05 was considered 
statistically significant. 
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Results 
Generation of VSMC-Specific Calcrl Deficient Mice. 
 To study the developmental and physiological role of CLR in vascular smooth 
muscle cells (VSMCs), we generated VSMC-specific Calcrl null mice.  CalcrlFlox/Flox 
mice were bred to Calcrl+/LoxP;SM22Cre+  mice that were heterozygous for the 
SM22Cre transgene that is specifically expressed in VSMCs [29, 34].  Genotyping 
was performed with genomic toe DNA from pups generated from the aforementioned 
cross and verified the four expected genotypes (Figure 5.1 A).  Importantly, only 
mice that expressed the SM22Cre+ transgene generated the recombined Calcrl 
allele through the Cre-mediated excision of exons 5 and 6.  For all experiments, 
CalcrlLoxP/LoxP;SM22Cre+ (VSMC-specific Calcrl null mice) and Calcrl+/LoxP;SM22Cre+ 
served as experimental and control mice, respectively.  The SM22Cre+ transgene 
was expressed in both control and experimental mice to ensure Cre recombinase 
toxicity could not contribute to differential phenotypes [35].   
 The resultant pups were born at expected Mendelian ratios and survived to 
adulthood without any obvious phenotypic defects (Figure 5.1A).  To verify that the 
SM22Cre mediated excision of the floxed Calcrl allele resulted decreased Calcrl 
gene expression, rtPCR was performed with RNA isolated from various mouse 
tissues including the VSMC-rich thoracic aorta.  As shown in Figure 5.1B, Calcrl 
gene expression was significantly decreased in the aortic VSMCs as well as the 
bladder and the heart of CalcrlLoxP/LoxP;SM22Cre+ mice relative to controls.  
Importantly, the SM22 Cre mediated excision was exclusive to these tissues as 
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previously reported [34].  Together, these data demonstrate that the expression of 
Calcrl in VSMCs is not required for  embryonic development and survival. 
 
Assessment of Basal Cardiovascular Function. 
To determine the effect of lack of Calcrl on VSMC function, blood pressure 
and heart rate was measure with tail-cuff on conscious adult mice.  A shown in 
Figure 5.2A-B, we found no significant difference between knockout and control 
animals.  Furthermore, to assess basal cardiovascular function and morphological 
parameters, echocardiography was performed on anesthetized mice from both 
experimental and control groups.  As shown in Table 5.1A, no significant differences 
were found for any of the physiological parameters measured including aortic 
diameter/contraction between the knockout and control mice.  All of the measured 
parameters fell within the range of previously reported values [36, 37].  Further, no 
differences were found in the gross histology of the heart (Figure 5.3) or in the cell 
thickness of the ascending aorta (7.0 ± 0.1 vs 6.9 ± 0.1) between knockout and 
control mice.  Lastly, Table 5.2B demonstrates no significant difference in body 
weight, heart size or metabolic responsiveness/kidney function between the two 
groups.  Taken together, these data strongly support that under basal conditions 
there are no cardiovascular deficiencies in mice lacking Calcrl in VSMCs.   
 
Responsiveness of the Vascular Smooth Muscle to Phenylephrine. 
          The lack of a basal cardiovascular phenotype suggested that other 
vasoregulatory VSMC mechanisms may have compensated for the loss of two 
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potent vasodilators CGRP and AM.  To test VSMC responsiveness in knockout and 
control mice, intra-arterial blood pressure measurements were taken in anesthetized 
mice after challenge with the α1-adrenergic receptor agonist, phenylephrine, over 
increasing doses of 30ug/kg, 60ug/kg, and 90ug/kg.  While both knockout and 
control mice showed the expected increases in MAP and corresponding decreases 
in HR, the percent change relative to baseline in the knockout mice was significantly 
less compared to control mice for both MAP and HR (Figure 5.4A-B).  Together, 
these data demonstrate that the lack of Calcrl in VSMCs resulted in a reduced 
response to phenylephrine, supporting a significant, yet unexpected role for CLR in 
VSMCs.   
 
Discussion 
The G-protein coupled receptor CLR functions as a receptor for two 
multifunctional, vasodilators AM and CGRP.  Many of the physiological functions of 
AM and CGRP occur in the cardiovascular system where CLR is expressed on the 
surface of ECs, VSMCs, and cardiomyocytes [11].  Global Calcrl knockout mice are 
embryonic lethality with defects in the proliferation of cardiovascular tissues 
including the lymphatic endothelium, vascular smooth muscle wall, and myocardium 
[8, 9].  To determine which cell type the loss of Calcrl leads to embryonic lethality, 
our lab has generated a conditional allele of Calcrl.  By breeding to either EC-
specific; cardiomyocyte-specific or VSMC-specific Cre lines, we are able to compare 
and contrast the outcomes and phenotypes in order to better elucidate the cellular 
role of Calcrl in development and cardiovascular physiology.  Remarkably, mice 
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lacking Calcrl specifically in ECs, using the Tie2Cre transgene, completely 
recapitulate the phenotype of the global Calcrl, AM and Ramp2 knockout mice 
strongly suggesting that AM signaling through the CLR-RAMP2 receptor complex in 
endothelial cells is necessary for embryonic development [9].  We have also shown 
that mice with Calcrl deleted in cardiomyocytes, using either the αMHCCre or 
cTNTCre transgenes, survive to adulthood (Dackor R, unpub. obs.).  In this study, 
we further show that mice which specifically lacked Calcrl in VSMCs, using the 
SM22Cre transgene, survive to adulthood.  Therefore, these comparative studies 
using conditional alleles demonstrate that the expression of Calcrl in ECs is required 
for survival, but that its expression in cardiomyocytes and VSMCs is dispersible.   
A number of studies have described both AM and CGRP as regulators of 
vascular tone by functioning as potent vasodilators.  Moreover, these data have 
supported a cardio-protective role in blood pressure regulation since plasma levels 
of both AM and CGRP are elevated during cardiovascular stresses including 
hypertension, pregnancy, and congestive heart failure (rev. in [2, 17]).  However, 
studies utilizing gene-targeted knockout mice of the AM/CGRP signaling 
components have failed to support an essential role for AM or CGRP in regulating 
basal blood pressure.  Two groups have independently found that modulating either 
AM, Cgrpα, or Ramp1 gene expression resulted in significant changes in basal blood 
pressure [10, 38-40].  In contrast, several other groups, including our laboratory, 
have failed to identify a significant role for AM or CGRP in regulating basal blood 
pressure.  For instance, we found that a genetic reduction or a genetic increase in 
AM expression levels had no effect on basal vascular tone [41]. Lu JT et al 
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exhaustively characterized mice lacking Cgrpα and found no impairment of basal 
cardiovascular function [42].  Further, decreased expression of Calcrl and Ramp2 
and global loss Ramp1 and Ramp3 did not affect basal blood pressure [[43], Li M in 
preparation].  Transgenic over-expression studies of Calcrl and Ramp2 in VSMCs 
revealed no change in basal blood pressure relative to control mice [44, 45].  In the 
present investigation, we found no differences in basal blood pressures and 
cardiovascular functions between VSMC-specific Calcrl deficient mice and controls.  
These data continue to support the concept that AM and CGRP signaling through 
VSMCs is dispensable for the regulation of basal vascular tone.   
Interestingly, VSMC-specific Calcrl deficient mice were found to be less 
sensitive to catecholomine mediated vasoconstriction when compared to controls.  
Since hemodynamic parameters are highly regulated through a variety of 
neuromuscular and hormonal mechanisms, these data would suggest that other 
mechanisms may be in place to compensate for the lack of two major vasodilators, 
by downregulating vasoconstrictor activity.  At first glance, these data would suggest 
that alpha adrenergic receptor expression may be down regulated in VSMC-specific 
Calcrl deficient mice lending to the decreased responsiveness to phenylephrine.    
Alternatively, since AM and CGRP generate a vasodilator response in VSMCs 
through a cAMP-mediated increase in activation of ATP-sensitive potassium 
channels and decreases in intracellular calcium levels (rev. in [17]), it would be 
interesting to investigate whether other interacting signaling cascades have been 
effected by loss of CLR.   
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In conclusion, this study details this first investigation to specifically examine 
the role of CLR signaling in VSMCs through generation of VSMC-specific Calcrl 
deficient mouse model.  We have found no difference in the initial characterization of 
knockout mice compared to control, suggesting CLR signaling is not necessary for 
the development or basal cardiovascular function in mouse models.   
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Figure 5.1:  Generation of VSMC-specific Calcrl deficient mice.  (A) PCR 
representing the four genotypes generated from the parent cross of CalcrlFlox/Flox x 
Caclrl+/LoxP;SM22Cre+.  The recombined “floxed” allele is only detected in SM22Cre+ 
mice and all mice were born at the expected Mendelian ratios.  (B) End-point RT-
PCR results of Calcrl gene expression in VSMCs, Heart, and Skeletal Muscle (Sk. 
Ms.) tissues collected from control and CalcrlLoxP/LoxP;SM22Cre+ animals.  A 
significant reduction in VSMC Calcrl gene expression is found in 
CalcrlLoxP/LoxP;SM22Cre+.   
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Figure 5.2:  Assessment of Basal Cardiovascular Function.  (A) Mean blood 
pressure of conscious Calcrl+/LoxP;SM22Cre+ and CalcrlLoxP/LoxP;SM22Cre+ mice 
measured by computerized tail cuff.  (B)  Heart rate of conscious 
Calcrl+/LoxP;SM22Cre+ and CalcrlLoxP/LoxP;SM22Cre+ mice.  No significant difference 
was found between the two groups (n=5).   
124 
 
Table 5.1 
Basal echocardiographic parameters of Calcrl+/LoxP; SM22Cre+ and 
CalcrlLoxP/LoxP; SM22Cre+ mice. 
 
        Calcrl+/LoxP; SM22Cre+    CalcrlLoxP/LoxP; SM22Cre+     P value 
N 5 6   
Heart Rate (bpm) 510±12 478±8
 
0.11 
LVED, d (mm) 3.75±0.16 4.00±0.11 0.24 
LVED, s (mm) 2.86±0.15 3.06±0.13 0.32 
LVPW, d (mm) 1.07±.0.08 0.92±0.04 0.14 
LVPW, s (mm) 1.28±0.08 1.13±0.07 0.19 
%FS 25.8±3.1
 
23.6±1.7 0.56 
%EF 48.8±6.2 47.4±2.9 0.85 
CO (ml/min) 16.0±2.0 15.3±0.7 0.86 
AortaD, d (mm) 1.49±0.05 1.38±0.07 0.25 
AortaD, s (mm) 1.29±0.07 1.22±0.06 0.69 
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Figure 5.3:  Examination of Calcrl+/LoxP;SM22Cre+ and CalcrlLoxP/LoxP;SM22Cre+ 
mice mouse hearts.  H & E stained left ventricles reveal no histological difference 
the two genotypes. Bar equals 1 mm.  
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Table 5.2  
Phenotypic Profiles of Calcrl+/LoxP; SM22Cre+ and CalcrlLoxP/LoxP; SM22Cre+ 
mice.  
 
 
       Calcrl+/LoxP; SM22Cre+   CalcrlLoxP/LoxP; SM22Cre+   P value 
 
 
 
 
 
 
Body Weight (g) 33.33±1.58 32.62±0.67
 
0.70 
Heart vs BW 
ratio 5.48±0.34 5.31±0.21 0.80 
Left Ventricle vs 
BW ratio 4.04±0.27 3.78±0.16 0.44 
Water 
intake(24h, ml) 4.2±0.4 4.4±0.2 0.32 
Urine Volume 
(24 h, ml 1.5± 0.2 1.4±0.3 0.88 
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Figure 5.4:  Reduced cardiovascular response in phenylephrine treated VSMC-
specific Calcrl deficient mice.  Increasing doses of phenylephrine were infused 
into the right jugular vein of anesthetized mice.  The CalcrlLoxP/LoxP;SM22Cre+ mice 
demonstrated a decreased response to phenylephrine compared to controls in both 
(A) percent change in mean arterial pressure (MAP) and (B) percent change in heart 
rate. (n=7, p<0.05)     
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CONCLUSIONS & FUTURE DIRECTIONS 
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This thesis describes the role of adrenomedullin signaling in the development 
and function of the cardiovascular system with specific attention to the lymphatic 
vasculature and vascular smooth muscle cells. In completing this thesis, several 
mouse models and cell culture systems were utilized to investigate a variety of 
biological and physiological questions.  Together, these findings represent important 
contributions to the field of adrenomedullin biology and will serve as building blocks 
for future studies.  This discussion highlights the key points found in each chapter 
and explores future endeavors which may proven beneficial in expanding our 
knowledge of adrenomedullin biology. 
 
Chapter 3 
Key Points 
1. AM signaling is necessary for murine lymphatic vascular development. 
2. AM, Ramp2, Calcrl and Calcrl endothelial-specific null mice develop 
generalized edema with hypoplastic lymph sacs due to a specific and 
preferential reduction in lymphatic endothelial cell proliferation during 
development. 
3. Calcrl is up-regulated in LECs by Prox1, suggesting that enriched AM 
signaling in LECs is necessary for embryonic survival. 
 
Future Directions 
 The early embryonic lethality in AM signaling null mice, while informative in 
contributing to our understanding of the necessity of AM signaling during 
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development, precludes our ability to pursue functional and mechanistic questions in 
later development and adulthood.  As such, I believe that the generation of two 
additional mouse models would greatly expand our understanding of AM signaling in 
endothelial cells. First, by utilizing the Cre-Lox system of conditional gene deletion, 
one could cross floxed Caclrl mice to a tamoxifen inducible Cre driven by an 
endothelial specific promoter (currently available include VE-Cadherin) [1]. Resultant 
mice generated from this cross would express normal Calcrl as a wildtype mouse, 
except when treated with tamoxifen, which would delete Calcrl specifically in 
endothelial cells. Thus, one could study the loss of AM signaling in endothelial cells 
during different developmental stages, and even in adulthood, to assess whether AM 
signaling in ECs is required for survival once the lymphatic vascular system has 
been established. Second, to examine whether AM signaling solely in ECs is 
sufficient for survival, one could over-express CLR in endothelial cells using an 
endothelial specific promoter (i.e. VE-Cadherin) and breed these mice onto the 
background of a global Calcrl null mouse by crossing to the Calcrl heterozygotes. A 
caveat to both of these proposed models is that we will be unable to distinguish 
between the effects of AM on blood versus lymphatic endothelium because the VE-
Cadherin promoter is expressed in both lineages.   At this time, a lymphatic 
endothelial-specific promoter has not been characterized to drive gene expression 
specifically in lymphatics.  However, if and when this tool becomes available, it 
would be very interesting to generate the two aforementioned mouse models in the 
context of lymphatic endothelial cells. This would allow one to evaluate whether AM 
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signaling specifically in LECs in necessary for survival and, through subtractive 
analysis, permit one to distinguish the role of AM signaling in LECs versus BECs.  
 Deciphering the endothelial specific intracellular pathways that are modulated 
by AM signaling could also provide valuable insight into understanding how AM 
signaling elicits its cellular effects. In Chapter 3, it was shown that AM stimulation 
activates MAPK in LECs to set forth the transcriptional events leading to increased 
proliferation. It would very interesting to know which other intracellular pathways are 
affected by loss of AM in terms of both expression and activity. To this end, primary 
WT and AM null ECs could be isolated and genome-wide microarrays could be 
performed to identify transcriptional targets that are downstream of AM signaling.  
These novel molecular players could then be functionally assessed using a variety of 
lymphangiogenic assays including: cultured mouse thoracic ducts and corneal 
neovascularization assays.  A highly likely potential pathway that could interact with 
AM signaling in LECs is the VEGF signaling cascade, which in itself is perhaps the 
most potent angiogenic pathway in endothelial cells.  Several studies, including work 
from the Caron lab, have suggested that AM signaling can augment VEGF signaling, 
resulting in an increased angiogenic response [2, 3]. In one study, a mechanism was 
suggested in which AM signaling through CLR transactivates the VEGF receptor [4].  
Cultured AM and Calcrl null EC, generated by stable siRNA expression, could be a 
valuable tool to further explore this mechanism. 
 Lastly, AM expression has been found to up-regulated in many forms of 
cancer and most likely promoted by the hypoxic conditions of the cancerous growth 
[5].  Currently, all of these studies have focused on the angiogenic properties of AM, 
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but the lymphangiogenic properties remain to be investigated.  By performing 
immunohistochemistry on the aforementioned tumor biopsies with lymphatic 
endothelial specific markers, one could determine whether increased AM expression 
correlates with increased lymphatic vessel density.  Based on the findings from this 
dissertation, one would expect a positive correlation of AM expression with lymphatic 
vessel density.  Assuming this to be true, the next logical step would be to generate 
anti-AM therapies to fight cancer growth and metastasis.  To this end, a current 
focus of our laboratory is in the generation and characterization of a small molecule 
inhibitor against AM activity which specifically targets the RAMP2-CLR extracellular 
domains.   
 
Chapter 4 
Key Points 
    1. AM stabilizes the lymphatic endothelial cell barrier in vitro by preventing VEGF 
mediated disruption of junctional proteins. 
    2. AM decreases lymphatic capillary permeability in vivo and completely 
abrogates VEGF increases in permeability. 
 
Future Directions 
 The intracellular signaling mechanism activated by AM to stabilize the LEC 
barrier remains unknown.  However, one model has been put forth by Hippenstiel et 
al from studies utilizing cultured blood endothelial.  They found that AM stabilized the 
EC barrier through a cAMP dependent relation of the micro filament system, 
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specifically inhibiting myosin-light chain phosphorylation and stress fiber formation 
[6].  While a similar mechanism may exist in LECs, we were unable to replicate 
these findings in the context of AM attenuating VEGF-mediated increases in 
permeability (data not shown).  Regardless, while the intracellular signaling 
mechanism may be unclear, the dramatic ability of AM to stabilize junctional proteins 
like VE-cadherin and ZO-1 at the plasma membrane in both LECs and BECs should 
be further investigated.  Indeed, the state of tyrosine phosphorylation of cadherins 
and their associated proteins can greatly influence the stability of adhaerens 
junctions [7, 8].  For instance, it has been well established that VEGF signaling 
through VEGFR-2 results in a phosphorylation event that directly leads to 
endocytosis of VE-cadherin and decreased barrier stability (i.e. increased 
permeability) [9].  Further, it has been suggested that the activities of RAP1, a RAS 
family GTPase, may play a vital role in cAMP directed stabilization of junctional 
complexes at the plasma membrane, specifically VE-cadherin [10].  As such, it may 
be worthwhile to explore the effect of AM signaling on junctional protein 
phosphorylation or RAP1 activation, in the hopes of providing a mechanism for our 
observations. 
 While the data presented in Chapter 3 demonstrate that AM functions to 
stabilize the lymphatic endothelial cell barrier in vitro and in vivo, it remains to be 
shown whether this function holds true during pathological conditions such as 
lymphedema, tumor metastasis, or dendritic cell trafficking during the immune 
response.  Generation of mouse models which specifically expresses Calcrl in the 
lymphatic endothelium at varying doses would greatly facilitate such studies.  Our 
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lab has recently generated a "gene-titration" mouse for the AM gene which could be 
applied to the Calcrl as well.  Briefly, the 3' UTR of the endogenous AM gene was 
replaced with a 3' UTR of bovine growth hormone (bGH) encompassed by flox sites 
and followed by a stop codon, which highly stabilized the AM mRNA transcipt 
leading to an increase mRNA half-life and a nearly three-fold increase in AM 
expression.  Further 3' to the bGH region, the 3' UTR of the C-fos gene, a highly 
unstable mRNA with a short half-life, was engineered into the targeting cassette as 
well.  Introduction of Cre recombinase excises the stabilizing bGH region, allowing 
transciption of the unstable C-fos region, resulting to a highly unstable AM mRNA 
transcript.  It would be very interesting to utilize the same approach for Calcrl and 
introduce Cre recombinase driven by a lymphatic endothelial-specific promoter, 
therefore generating mice with modulated AM signaling by either over-expressing 
Calcrl or under-expressing Calcrl in the lymphatic endothelium.  These mice could 
then be utilized for studies investigating the role of AM signaling in the lymphatic 
endothelium during pathological conditions.  
 
Chapter 5 
Key Points 
1. Since global knockouts of AM signaling components are embryonic lethal, 
VSMC-specific Calcrl knockouts were generated to determine the cell-specific 
cause of embryonic lethality.  This was accomplished by introducing Cre 
recombinase driven by the VMSC-specific promoter SM22 into the 
background of “floxed” Calcrl mice.    
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2. VSMC-specific Calcrl deficient mice were born at expected Mendelian ratios 
and survived to adulthood with no obvious functional defects.  Therefore, the 
CLR mediated signaling events of AM or CGRP ligand binding are 
dispensable for murine vascular development. 
3. Consistent with our previous studies, we observed no differences in basal 
blood pressure or cardiac function in VSMC-specific Calcrl deficient mice 
compared to control mice.  Thus, CLR mediated signaling events are not 
essential for maintaining basal hemodynamics. 
4. Unexpectedly, VSMC-specific Calcrl deficient mice displayed a reduced 
response to induced vasoconstriction by the α-adrenergic receptor agonist 
phenylephrine compared to control mice.  This suggest that other 
hemodynamic regulators may have compensated for the loss of AM and 
CGRP signaling in the vascular smooth muscle. 
 
Future Directions 
Over the past decade much debate has been generated on whether AM and 
CGRP function as essential regulators of basal vascular tone.  To date, at least 8 
independent studies have specifically examined either AM or CGRP signaling in 
genetic altered mice including AM, Calcrl, and Ramp2 heterozygote mice, CGRP 
knockout mice, VSMC-specific Calcrl over-expressing mice, VSMC-specific Ramp2 
over-expressing mice, and global knockouts of Ramp1 and Ramp3 [10-19] .  The 
majority of these studies, with the exception studies from two laboratories, have 
rebuked the hypothesis that AM and CGRP are potent vasodilators contributing to 
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basal hemodynamics.  The present study directly addressed this debate through the 
generation and characterization of VSMC-specific Calcrl deficient mice.  Our results 
strongly confirm a non-essential role for AM and CGRP signaling in the regulation of 
basal blood pressure.   
However, the role of these signaling pathways during pathological conditions 
remains to be resolved.  Therefore, we chose to challenge the VSMC-specific Calcrl 
deficient mice with pharmacological vasoconstriction, expecting the mice would 
show greater vasoconstriction in the absence of two potent endogenous 
vasodilators.  Unexpectedly, we found a decreased change in mean arterial 
pressure after stimulation with phenylephrine in the VSMC-specific Calcrl deficient 
mice.  These results suggest that other hemodynamic mechanisms may be 
compensating for the loss of AM and CGRP vasodilator functions in the VSMC-
specific Calcrl mice.   
It would be interesting to extend these studies to mouse models of acute 
hypertension by aortic constriction or chronic hypertension through the introduction 
of the renin transgene [20] to elucidate the role of AM and CGRP signaling in 
VSMCs during the diseased state.  In addition, these proposed studies would allow 
us to challenge the postulated compensatory mechanisms over an extended period 
of time. 
The lack of an observed hypertensive response in the VSMC-specific Calcrl 
deficient mice also leaves open the possibility that AM and CGRP signaling in the 
endothelium could be solely responsible for coordinating the vasodilator activities of 
AM and CGRP most likely through a nitric oxide-dependent mechanism (see Figure 
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1.3).  It is currently difficult to address this hypothesis directly because the 
endothelial-specific Calcrl mice die during embryogenesis.  However, utilization of an 
endothelial specific tamoxifen-inducible Cre mouse [1], to excise Calcrl postnatally 
from the vascular endothelium could serve as a very powerful tool.   
Because the functional role of CLR in mediating smooth muscle cell tone may 
be less relevant to the vasculature but more important in other tissues like the lung 
and the uterus, the current VSMC-specific Calcrl deficient mouse may be useful to 
study pathological conditions in these tissues. 
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APPENDIX 
 
SUPPLEMENTARY INFORMATION FROM CHAPTER 3: ADRENOMEDULLIN 
SIGNALING IS ESSENTIAL FOR MURINE LYMPHATIC VASCULAR 
DEVELOPMENT 
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Supplemental Expanded Methods 
Tissue Preparation, Immunohistochemistry and Microscopy 
Tissues or cells, plated on glass coverslips, were fixed in 4% 
paraformaldehyde in PBS overnight.  For immunofluorescent staining, tissues were 
then cryoprotected with 30% sucrose in PBS overnight, embedded in OCT (Tissue-
Tek) and cryosectioned at 6-8µm.  Sections or cells were rehydrated in PBS, 
permeablized with 0.4% Triton-X100 in PBS, blocked with 4% BSA in PBS and 
incubated in primary antibody overnight.  After washing, fluorescently labeled 
secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were incubated 
for 2 hours at room temperature, sections were washed and mounted for imaging.  
EGFP was imaged immediately after permeablization.  Images were acquired on a 
Nikon E800 microscope with a Hammamatsu ORCA-ER CCD camera using 
Metamorph Software (Molecluar Devices) and processed in Photoshop8.0 (Adobe).  
For hematoxylin and eosin staining, fixed tissues were put through an ethanol 
gradient, embedded in paraffin and sectioned at 10µm.  Sections were 
deparaffinized and stained with Mayer’s hematoxylin and eosin following standard 
protocols. 
 
Quantitative RT-PCR 
Lymphatic vessels were isolated from the hind limbs of adult SvEv129/6 mice.  
Briefly, the hind footpads of anesthetized mice were injected with 3% Chicago sky 
blue in Tyrode’s Buffer.  After incorporation, mice were euthanized and lymphatic 
vessels labeled with blue dye were excised under a dissecting microscope.  RNA 
149 
 
was isolated using the RNeasy Micro kit (Qiagen, Valencia, CA) with additional 
DNAse treatment (Promega).  RNA from embryos and cultured cells was isolated 
using the RNeasy Mini kit.  cDNA was then generated using the iScript Select cDNA 
synthesis kit (Bio-Rad, Hurcules, CA). 
Quantitative PCR was performed on the Stratagene Mx-3000p machine (La 
Jolla, CA) using ABgene ROX master mix (Rochester, NY) and rodent GAPDH 
control reagents (Applied Biosystems, Foster City, CA). Relative levels of gene 
expression were determined using the comparative quantitation (∆∆CT) method with 
MxPro software (Stratagene).  Sequences for the mouse AM, calcrl and RAMP2 
primers and probes have been published (33-35) and all other primer and probe 
sequences are provided in Supplemental Figure 6 online.   All assays were repeated 
at least twice, and all samples were run in triplicate. Results were analyzed using the 
two-tailed Student’s t-test assuming unequal variance. 
 
Interstitial fluid analysis 
To collect interstitial fluid from homozygous null embryos, RAMP2-/- E14.5 
embryos were dissected in PBS.  A 30.5 gauge needle was inserted under the 
edematous skin and fluid was slowly drained.  Rat lymph was collected directly from 
the thoracic duct of an adult Sprague-Dawley rat and mouse serum was collected by 
tail bleed from adult SvEv129/6 mice. Samples were centrifuged at 30,000x g and 
supernatants were loaded onto 8-12% gradient polyacrlymide tris-glycine gels.  Gels 
were stained with coomassie blue 250 (Sigma.) 
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Quantification of Lymph Sac Area  
Hematoxylin and eosin stained transverse sections of the jugular region of 
AM, calcrl and RAMP2 null embryos were imaged on a Leica MZ16 dissecting 
microscope.  Sections containing jugular lymph sacs that were matched for the 
same anteroposterior level were blindly measured using ImageJ software (NIH, 
USA).  In order to normalize for section variability, the area of the lymph sac (defined 
as the area within the perimeter) was divided by the area of the adjacent jugular 
vein. 
 
Transmission Electron Microscopy 
Embryos were collected and fixed in 2% formaldehyde/2.5% glutaraldehyde 
in 0.15M sodium phosphate buffer, pH 7.4, overnight at 4˚C. Following several 
washes in sodium phosphate buffer, the samples were post-fixed for 1 hour in 
potassium ferrocyanide-reduced osmium, dehydrated through a graded series of 
ethanol and embedded in PolyBed 812 epoxy resin (Polysciences, Warrington, PA). 
Using a diamond knife, 1 m cross-sections were cut, stained with 1% toluidine blue 
and examined by light microscopy to isolate areas containing jugular lymph sacs. 
Ultrathin sections were cut with a diamond knife (70-80 nm thickness), mounted on 
200 mesh copper grids and stained with 4% aqueous uranyl acetate for 15 minutes 
followed by Reynolds’ lead citrate for 8 minutes. The sections were observed using a 
LEO EM-910 transmission electron microscope (LEO Electron Microscopy, Inc., 
Thornwood, NY), accelerating voltage of 80 kV, and micrographs were taken using a 
Gatan Orius SC 1000 CCD Camera (Gatan, Inc., Pleasanton, CA). 
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In Cell Western 
8x104 cells/ml were cultured under normal growth conditions and after 24 
hours media was changed to basic medium containing 0.5% FBS for 24 hours.  
Cells were then treated with 10nm AM for indicated times.  At the end of incubation, 
the medium was removed and the cells were fixed, permeabilized, blocked, and 
treated with the appropriate antibodies per manufacturer’s instructions (LI-COR).  
The primary antibodies, anti-phosph-ERK1/2 and anti-ERK1/2, were used at 
dilutions 1:100 and 1:25, respectively, and detected with goat-anti-mouse IR680 and 
goat-anti-rabbit IR800 each at 1:5000 dilutions.  The plates were scanned with the 
Odyssey infrared scanner, data was obtained using scanner software and total area 
under the curve was determined by Gaussian best-fit analysis. 
 
Western Blotting 
LECs were treated with 10nm AM for indicated time points, washed three 
times with PBS, lysed in 100µl of sample buffer, boiled for 10 min, loaded onto a 
10% polyacrylimide gel and resolved by SDS-PAGE.  Protein was then transferred 
to a polyvinylidene diflouride (PVDF) membrane which was subsequently blocked in 
5% non-fat dry milk overnight at 4 degrees. The primary antibodies were incubated 
overnight at 4 degrees at 1 mg/ml and detected with secondary antibodies as 
described for the In Cell Western above.  The blot was imaged with the Odyssey 
infrared scanner and data was obtained using scanner software. 
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Supplemental Figure 1:  Developmental cardiovascular defects of RAMP2-/- 
embryos phenocopies those of AM-/- and calcrl-/- embryos.  Histological 
sections from E14.5 wildtype and RAMP2-/- embryos stained with H&E.  The 
RAMP2-/- embryos had generally smaller hearts than wildtype littermates 
(A,B) with overtly normal artia, ventricles, valves and septum.  The thickness 
of the compact zone of the right ventricle (RV) was significantly diminished in 
RAMP2-/- embryos compared to wildtype littermate controls (C,D).  While the 
endothelial lining of aortas (Ao) from RAMP2-/- embryos appeared 
indistinguishable from that of wildtype littermates, there was a remarkable 
reduction in the extent of vascular smooth muscle coverage in RAMP2-/- 
embryos compared to wildtype (E,F).  In summary, RAMP2-/- embryos 
displayed developmental cardiovascular defects similar to those previously 
reported for AM-/-  and calcrl-/- mice. 
153 
 
 
 
Supplemental Figure 2: Interstitial fluid removed from RAMP2-/- embryos 
contains high molecular weight proteins.  Fluid was removed from an E13.5 
RAMP2-/- embryo and centrifuged to remove cellular debris.  The supernatant was 
resolved on an SDS-PAGE gel along with lymph obtained directly from the thoracic 
duct of a rat, and mouse serum.  Commassie staining shows that the edematous 
fluid contains an abundance of albumin (67kD) and numerous other high molecular 
weight proteins (>100kD), typical of lymph and unlike serum. 
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Supplemental Figure 3:  Lymph sacs in developing E14.5 embryos are not 
lined by smooth muscle cells.  (A-D) Immunofluorescent staining of transverse 
sections through the jugular region of WT embryos. Newly formed lymph sacs (LS) 
which are lined with VEGFR3-containing endothelial cells (panel A:green, panel C) 
are not surrounded by smooth muscle, as indicated by lack of a SM-actin staining 
(panel A:red, panel B:arrows).  Smooth muscle staining can be seen around the 
carotid artery (A) and jugular vein (V) of panels A and B.  Hoechst stained nuclei are 
shown in panel D and indicated in blue in panel A.  Inset in panel A shows no 
primary antibody control. 
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Supplemental Movie 4:  High resolution, signal volume rendered, 3-Dimensional 
movie of fluorescent immunohistochemistry on an E14.5 wildtype embryo using 
VEGFR3 antibody to visualize lymphatic vascular development.  This movie can be 
viewed at http://www.jci.org/articles/view/33302/sd/2. 
 
Supplemental Movie 5:  High resolution, signal volume rendered, 3-Dimensional 
movie of fluorescent immunohistochemistry on an E14.5 RAMP2-/- embryo using 
VEGFR3 antibody to visualize lymphatic vascular development.  This movie can be 
viewed at http://www.jci.org/articles/view/33302/sd/3. 
 
 
Supplemental Figure 6: Primers and Probes used for Genotyping and Gene 
Expression Analysis.  
